Multiple sclerosis (English Wikipedia)

Saguil A, Farnell IV EA, Jordan TS (August 2022). "Multiple Sclerosis: A Primary Care Perspective". American Family Physician. 106 (2): 173–183. PMID 35977131.

aan.com (Global: low place; English: low place)

continuum.aan.com

Ward M, Goldman MD (August 2022). "Epidemiology and Pathophysiology of Multiple Sclerosis". Continuum. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136.

archive.org (Global: 6^th place; English: 6^th place)

Barbellion WN (1919). The Journal of a Disappointed Man. New York: George H. Doran. ISBN 0-7012-1906-8. {{cite book}}: ISBN / Date incompatibility (help)

atlasofms.org (Global: low place; English: low place)

"Number of people with MS | Atlas of MS". atlasofms.org. Retrieved 24 June 2025.

bbc.com (Global: 20^th place; English: 30^th place)

Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (January 2022). "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis". Science. 375 (6578): 296–301. Bibcode:2022Sci...375..296B. doi:10.1126/science.abj8222. PMID 35025605. S2CID 245983763. See lay summary: Gallagher J (13 April 2022). "Is a virus we all have causing multiple sclerosis?". BBC. Archived from the original on 25 April 2022. Retrieved 14 April 2022.
Roxby P (10 January 2024). "Scientists crack mystery of how MS gene spread". BBC News. Archived from the original on 11 January 2024. Retrieved 11 January 2024.

biogenidec.com (Global: low place; English: low place)

"Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis" (Press release). Biogen Idec. 27 March 2013. Archived from the original on 12 May 2013. Retrieved 4 June 2013.

books.google.com (Global: 3^rd place; English: 3^rd place)

Keegan BM (22 December 2011). "Multiple Sclerosis". In Bope ET, Kellerman RD (eds.). Conn's Current Therapy 2012: Expert Consult – Online and Print. Elsevier Health Sciences. p. 626. ISBN 978-1-4557-0738-6.

doi.org (Global: 2^nd place; English: 2^nd place)

Compston A, Coles A (October 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–1517. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977. S2CID 195686659.
Milo R, Kahana E (March 2010). "Multiple sclerosis: geoepidemiology, genetics and the environment". Autoimmunity Reviews. 9 (5): A387-94. doi:10.1016/j.autrev.2009.11.010. PMID 19932200.
Nakahara J, Maeda M, Aiso S, Suzuki N (February 2012). "Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy". Clinical Reviews in Allergy & Immunology. 42 (1): 26–34. doi:10.1007/s12016-011-8287-6. PMID 22189514. S2CID 21058811.
Liu Z, Liao Q, Wen H, Zhang Y (June 2021). "Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis". Autoimmunity Reviews. 20 (6) 102826. doi:10.1016/j.autrev.2021.102826. PMID 33878488. S2CID 233325057.
Alphonsus KB, Su Y, D'Arcy C (April 2019). "The effect of exercise, yoga and physiotherapy on the quality of life of people with multiple sclerosis: Systematic review and meta-analysis". Complementary Therapies in Medicine. 43: 188–195. doi:10.1016/j.ctim.2019.02.010. PMID 30935529. S2CID 86669723.
Compston A, Coles A (April 2002). "Multiple sclerosis". Lancet. 359 (9313): 1221–1231. doi:10.1016/S0140-6736(02)08220-X. PMID 11955556. S2CID 14207583.
Piryonesi SM, Rostampour S, Piryonesi SA (April 2021). "Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms". Multiple Sclerosis and Related Disorders. 49 102740. doi:10.1016/j.msard.2021.102740. PMID 33450500. S2CID 231624230.
Mazumder R, Murchison C, Bourdette D, Cameron M (25 September 2014). "Falls in people with multiple sclerosis compared with falls in healthy controls". PLOS ONE. 9 (9) e107620. Bibcode:2014PLoSO...9j7620M. doi:10.1371/journal.pone.0107620. PMC 4177842. PMID 25254633.
Ford H (July 2020). "Clinical presentation and diagnosis of multiple sclerosis". Clinical Medicine. 20 (4). London, England: 380–383. doi:10.7861/clinmed.2020-0292. ISSN 1473-4893. PMC 7385797. PMID 32675142.
Baecher-Allan C, Kaskow BJ, Weiner HL (February 2018). "Multiple Sclerosis: Mechanisms and Immunotherapy". Neuron. 97 (4): 742–768. doi:10.1016/j.neuron.2018.01.021. PMID 29470968. S2CID 3499974.
^{[medical citation needed]}Lublin FD, Reingold SC (April 1996). "Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology. 46 (4): 907–911. doi:10.1212/WNL.46.4.907. PMID 8780061. S2CID 40213123.
Loma I, Heyman R (September 2011). "Multiple sclerosis: pathogenesis and treatment". Current Neuropharmacology. 9 (3): 409–416. doi:10.2174/157015911796557911. PMC 3151595. PMID 22379455.
Ward M, Goldman MD (August 2022). "Epidemiology and Pathophysiology of Multiple Sclerosis". Continuum. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. PMID 35938654. S2CID 251375096.
Aloisi F, Cross AH (October 2022). "MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis". Journal of Neuroimmunology. 371 577935. doi:10.1016/j.jneuroim.2022.577935. PMID 35931008. S2CID 251152784.
Ascherio A, Munger KL (April 2007). "Environmental risk factors for multiple sclerosis. Part I: the role of infection". Annals of Neurology. 61 (4): 288–299. doi:10.1002/ana.21117. PMID 17444504. S2CID 7682774.
McGinley MP, Goldschmidt CH, Rae-Grant AD (February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765–779. doi:10.1001/jama.2020.26858. PMID 33620411. S2CID 232019589.
Quinn É, Hynes SM (July 2021). "Occupational therapy interventions for multiple sclerosis: A scoping review". Scandinavian Journal of Occupational Therapy. 28 (5): 399–414. doi:10.1080/11038128.2020.1786160. hdl:10379/16066. PMID 32643486. S2CID 220436640.
Weinshenker BG (1994). "Natural history of multiple sclerosis". Annals of Neurology. 36 (Suppl): S6-11. doi:10.1002/ana.410360704. PMID 8017890. S2CID 7140070.
Wecker S, Freudenstein D, Ganser I, Angstwurm K, Lee DH, Linker RA (2024). "The impact of different lifestyle factors on disability in multiple sclerosis at older ages: a monocentric retrospective study". Therapeutic Advances in Neurological Disorders. 17 17562864241284166. doi:10.1177/17562864241284166. ISSN 1756-2856. PMC 11528639. PMID 39494114.
Dobson R, Giovannoni G (2019). "Multiple sclerosis – a review". European Journal of Neurology. 26 (1): 27–40. doi:10.1111/ene.13819. ISSN 1468-1331. PMID 30300457.
Berer K, Krishnamoorthy G (November 2014). "Microbial view of central nervous system autoimmunity". FEBS Letters. 588 (22): 4207–13. Bibcode:2014FEBSL.588.4207B. doi:10.1016/j.febslet.2014.04.007. PMID 24746689. S2CID 2772656.
Lane J, Ng HS, Poyser C, Lucas RM, Tremlett H (July 2022). "Multiple sclerosis incidence: A systematic review of change over time by geographical region". Mult Scler Relat Disord. 63 103932. doi:10.1016/j.msard.2022.103932. PMID 35667315. S2CID 249188137.
Dobson R, Giovannoni G (2019). "Multiple sclerosis – a review". European Journal of Neurology. 26 (1): 27–40. doi:10.1111/ene.13819. ISSN 1468-1331. PMID 30300457.
Moore H, Nair KP, Baster K, Middleton R, Paling D, Sharrack B (August 2022). "Fatigue in multiple sclerosis: A UK MS-register based study". Multiple Sclerosis and Related Disorders. 64 103954. doi:10.1016/j.msard.2022.103954. PMID 35716477.
Bakalidou D, Giannopapas V, Giannopoulos S (July 2023). "Thoughts on Fatigue in Multiple Sclerosis Patients". Cureus. 15 (7) e42146. doi:10.7759/cureus.42146. PMC 10438195. PMID 37602098.
Plotas P, Nanousi V, Kantanis A, Tsiamaki E, Papadopoulos A, Tsapara A, et al. (July 2023). "Speech deficits in multiple sclerosis: a narrative review of the existing literature". European Journal of Medical Research. 28 (1) 252. doi:10.1186/s40001-023-01230-3. PMC 10364432. PMID 37488623.
Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, et al. (December 2022). "Diagnosis and classification of optic neuritis". The Lancet. Neurology. 21 (12): 1120–1134. doi:10.1016/s1474-4422(22)00200-9. hdl:2078.1/276419. PMID 36179757.
Cameron MH, Nilsagard Y (2018). "Balance, gait, and falls in multiple sclerosis". In Day BL, Lord SR (eds.). Balance, Gait, and Falls. Handbook of Clinical Neurology. Vol. 159. pp. 237–250. doi:10.1016/b978-0-444-63916-5.00015-x. ISBN 978-0-444-63916-5. PMID 30482317.
Ghasemi N, Razavi S, Nikzad E (January 2017). "Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy". Cell Journal. 19 (1): 1–10. doi:10.22074/cellj.2016.4867 (inactive 1 July 2025). PMC 5241505. PMID 28367411.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
Chen MH, Wylie GR, Sandroff BM, Dacosta-Aguayo R, DeLuca J, Genova HM (August 2020). "Neural mechanisms underlying state mental fatigue in multiple sclerosis: a pilot study". Journal of Neurology. 267 (8): 2372–2382. doi:10.1007/s00415-020-09853-w. PMID 32350648.
Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez MÁ, Meca-Lallana V, Ramió-Torrentà L (2019). "Cognitive Dysfunctions and Assessments in Multiple Sclerosis". Frontiers in Neurology. 10 581. doi:10.3389/fneur.2019.00581. PMC 6558141. PMID 31214113.
Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. (November 2018). "Recommendations for cognitive screening and management in multiple sclerosis care". Multiple Sclerosis. 24 (13): 1665–1680. doi:10.1177/1352458518803785. PMC 6238181. PMID 30303036.
Benedict RH, Amato MP, DeLuca J, Geurts JJ (October 2020). "Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues". The Lancet. Neurology. 19 (10): 860–871. doi:10.1016/S1474-4422(20)30277-5. PMC 10011205. PMID 32949546. S2CID 221744328.
Christogianni A, Bibb R, Davis SL, Jay O, Barnett M, Evangelou N, et al. (17 January 2018). "Temperature sensitivity in multiple sclerosis: An overview of its impact on sensory and cognitive symptoms". Temperature. 5 (3): 208–223. doi:10.1080/23328940.2018.1475831. PMC 6205043. PMID 30377640.
Kurtzke JF (November 1983). "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)". Neurology. 33 (11): 1444–52. doi:10.1212/WNL.33.11.1444. PMID 6685237.
Amato MP, Ponziani G (August 1999). "Quantification of impairment in MS: discussion of the scales in use". Multiple Sclerosis. 5 (4): 216–9. doi:10.1177/135245859900500404. PMID 10467378. S2CID 6763447.
Rudick RA, Cutter G, Reingold S (October 2002). "The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials". Multiple Sclerosis. 8 (5): 359–65. doi:10.1191/1352458502ms845oa. PMID 12356200. S2CID 31529508.
van Munster CE, Uitdehaag BM (March 2017). "Outcome Measures in Clinical Trials for Multiple Sclerosis". CNS Drugs. 31 (3): 217–236. doi:10.1007/s40263-017-0412-5. PMC 5336539. PMID 28185158.
Makhani N, Tremlett H (August 2021). "The multiple sclerosis prodrome". Nature Reviews. Neurology. 17 (8): 515–521. doi:10.1038/s41582-021-00519-3. PMC 8324569. PMID 34155379.
Marrie RA (December 2019). "Mounting evidence for a multiple sclerosis prodrome". Nature Reviews. Neurology. 15 (12): 689–690. doi:10.1038/s41582-019-0283-0. PMID 31654040. S2CID 204887642.
Tataru N, Vidal C, Decavel P, Berger E, Rumbach L (2006). "Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis". Neuroepidemiology. 27 (1): 28–32. doi:10.1159/000094233. PMID 16804331. S2CID 20870484.
Heesen C, Mohr DC, Huitinga I, Bergh FT, Gaab J, Otte C, et al. (March 2007). "Stress regulation in multiple sclerosis: current issues and concepts". Multiple Sclerosis. 13 (2): 143–148. doi:10.1177/1352458506070772. PMID 17439878. S2CID 8262595.
Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S (February 2001). "Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group". The New England Journal of Medicine. 344 (5): 319–326. doi:10.1056/NEJM200102013440501. PMID 11172162.
Grimaldi L, Papeix C, Hamon Y, Buchard A, Moride Y, Benichou J, et al. (October 2023). "Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups". JAMA Neurology. 80 (10): 1098–1104. doi:10.1001/jamaneurol.2023.2968. PMC 10481324. PMID 37669073.
Martinelli V (2000). "Trauma, stress and multiple sclerosis". Neurological Sciences. 21 (4 Suppl 2): S849 – S852. doi:10.1007/s100720070024. PMID 11205361. S2CID 2376078.
Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA (April 2019). "UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines". Practical Neurology. 19 (2): 106–114. doi:10.1136/practneurol-2018-002060. PMID 30612100.
Varytė G, Zakarevičienė J, Ramašauskaitė D, Laužikienė D, Arlauskienė A (January 2020). "Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity". Medicina. 56 (2): 49. doi:10.3390/medicina56020049. PMC 7074401. PMID 31973138.
Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. (November 2007). "Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain". The Journal of Experimental Medicine. 204 (12): 2899–2912. doi:10.1084/jem.20071030. PMC 2118531. PMID 17984305.
Hassani A, Corboy JR, Al-Salam S, Khan G (2018). "Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells". PLOS ONE. 13 (2) e0192109. Bibcode:2018PLoSO..1392109H. doi:10.1371/journal.pone.0192109. PMC 5796799. PMID 29394264.
Lutterotti A, Hayward-Koennecke H, Sospedra M, Martin R (2021). "Antigen-Specific Immune Tolerance in Multiple Sclerosis-Promising Approaches and How to Bring Them to Patients". Frontiers in Immunology. 12 640935. doi:10.3389/fimmu.2021.640935. PMC 8019937. PMID 33828551.
Ward M, Goldman MD (August 2022). "Epidemiology and Pathophysiology of Multiple Sclerosis". Continuum. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136.
McGinley MP, Goldschmidt CH, Rae-Grant AD (23 February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765. doi:10.1001/jama.2020.26858. ISSN 0098-7484.
Gilden DH (March 2005). "Infectious causes of multiple sclerosis". The Lancet. Neurology. 4 (3): 195–202. doi:10.1016/S1474-4422(05)01017-3. PMC 7129502. PMID 15721830.
Soldan SS, Lieberman PM (January 2023). "Epstein-Barr virus and multiple sclerosis". Nature Reviews. Microbiology. 21 (1): 51–64. doi:10.1038/s41579-022-00770-5. PMC 9362539. PMID 35931816.
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (January 2022). "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis". Science. 375 (6578): 296–301. Bibcode:2022Sci...375..296B. doi:10.1126/science.abj8222. PMID 35025605. S2CID 245983763. See lay summary: Gallagher J (13 April 2022). "Is a virus we all have causing multiple sclerosis?". BBC. Archived from the original on 25 April 2022. Retrieved 14 April 2022.
Münz C (May 2004). "Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target". The Journal of Experimental Medicine. 199 (10): 1301–1304. doi:10.1084/jem.20040730. PMC 2211815. PMID 15148332.
Miclea A, Bagnoud M, Chan A, Hoepner R (6 May 2020). "A Brief Review of the Effects of Vitamin D on Multiple Sclerosis". Frontiers in Immunology. 11 781. doi:10.3389/fimmu.2020.00781. PMC 7218089. PMID 32435244.
Dyment DA, Ebers GC, Sadovnick AD (February 2004). "Genetics of multiple sclerosis". The Lancet. Neurology. 3 (2): 104–10. CiteSeerX 10.1.1.334.1312. doi:10.1016/S1474-4422(03)00663-X. PMID 14747002. S2CID 16707321.
Skene NG, Grant SG (2016). "Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment". Frontiers in Neuroscience. 10: 16. doi:10.3389/fnins.2016.00016. PMC 4730103. PMID 26858593.
Hassan-Smith G, Douglas MR (October 2011). "Epidemiology and diagnosis of multiple sclerosis". British Journal of Hospital Medicine. 72 (10): M146-51. doi:10.12968/hmed.2011.72.Sup10.M146. PMID 22041658.
Rosati G (April 2001). "The prevalence of multiple sclerosis in the world: an update". Neurological Sciences. 22 (2): 117–39. doi:10.1007/s100720170011. PMID 11603614. S2CID 207051545.
Baranzini SE (June 2011). "Revealing the genetic basis of multiple sclerosis: are we there yet?". Current Opinion in Genetics & Development. 21 (3): 317–24. doi:10.1016/j.gde.2010.12.006. PMC 3105160. PMID 21247752.
International Multiple Sclerosis Genetics Consortium (2019). "Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility". Science. 365 (6460) eaav7188. doi:10.1126/science.aav7188. PMC 7241648. PMID 31604244.
Simpson S, Wang W, Otahal P, Blizzard L, van der Mei IA, Taylor BV (November 2019). "Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 90 (11): 1193–1200. doi:10.1136/jnnp-2018-320189. PMID 31217172.
Pugliatti M, Sotgiu S, Rosati G (July 2002). "The worldwide prevalence of multiple sclerosis". Clinical Neurology and Neurosurgery. 104 (3): 182–91. doi:10.1016/S0303-8467(02)00036-7. PMID 12127652. S2CID 862001.
Grimaldi LM, Salemi G, Grimaldi G, Rizzo A, Marziolo R, Lo Presti C, et al. (November 2001). "High incidence and increasing prevalence of MS in Enna (Sicily), southern Italy". Neurology. 57 (10): 1891–3. doi:10.1212/wnl.57.10.1891. PMID 11723283. S2CID 34895995.
Marrie RA (December 2004). "Environmental risk factors in multiple sclerosis aetiology". The Lancet. Neurology. 3 (12): 709–18. doi:10.1016/S1474-4422(04)00933-0. PMID 15556803. S2CID 175786.
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009). "Vitamin D: an evidence-based review". Journal of the American Board of Family Medicine. 22 (6): 698–706. doi:10.3122/jabfm.2009.06.090037. PMID 19897699.
Sintzel MB, Rametta M, Reder AT (1 June 2018). "Vitamin D and Multiple Sclerosis: A Comprehensive Review". Neurology and Therapy. 7 (1): 59–85. doi:10.1007/s40120-017-0086-4. ISSN 2193-6536. PMC 5990512. PMID 29243029.
Olsson T, Barcellos LF, Alfredsson L (January 2017). "Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis". Nature Reviews Neurology. 13 (1): 25–36. doi:10.1038/nrneurol.2016.187. ISSN 1759-4766. PMID 27934854.
Vitturi BK, Montecucco A, Rahmani A, Dini G, Durando P (15 November 2023). "Occupational risk factors for multiple sclerosis: a systematic review with meta-analysis". Frontiers in Public Health. 11 (2023): Introduction, Results. Bibcode:2023FrPH...1185103V. doi:10.3389/fpubh.2023.1285103. PMC 10694508. PMID 38054069.
Stowe J, Andrews N, Miller E (January 2020). "Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barré Syndrome and Narcolepsy". CNS Drugs. 34 (1): 1–8. doi:10.1007/s40263-019-00670-y. PMC 7224038. PMID 31576507.
Ascherio A, Munger KL (June 2007). "Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors". Annals of Neurology. 61 (6): 504–13. doi:10.1002/ana.21141. PMID 17492755. S2CID 36999504.
Spitsin S, Koprowski H (2008). "Role of Uric Acid in Multiple Sclerosis". In Rodriguez M (ed.). Advances in multiple Sclerosis and Experimental Demyelinating Diseases. Current Topics in Microbiology and Immunology. Vol. 318. pp. 325–342. doi:10.1007/978-3-540-73677-6_13. ISBN 978-3-540-73676-9. PMID 18219824.
Nourbakhsh B, Mowry EM (June 2019). "Multiple Sclerosis Risk Factors and Pathogenesis". Continuum. 25 (3): 596–610. doi:10.1212/CON.0000000000000725. PMID 31162307. S2CID 174806511.
Miclea A, Bagnoud M, Chan A, Hoepner R (6 May 2020). "A Brief Review of the Effects of Vitamin D on Multiple Sclerosis". Frontiers in Immunology. 11 781. doi:10.3389/fimmu.2020.00781. ISSN 1664-3224. PMC 7218089. PMID 32435244.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. (February 2018). "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria". The Lancet. Neurology. 17 (2): 162–173. doi:10.1016/s1474-4422(17)30470-2. PMID 29275977. Archived from the original on 28 May 2023. Retrieved 20 January 2024.
Hassani A, Reguraman N, Shehab S, Khan G (2021). "Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis". Frontiers in Immunology. 12 764937. doi:10.3389/fimmu.2021.764937. PMC 8656284. PMID 34899715.
Chari DM (2007). "Remyelination in Multiple Sclerosis". In Minagar A (ed.). The Neurobiology of Multiple Sclerosis. International Review of Neurobiology. Vol. 79. pp. 589–620. doi:10.1016/S0074-7742(07)79026-8. ISBN 978-0-12-373736-6. PMC 7112255. PMID 17531860.
Pittock SJ, Lucchinetti CF (March 2007). "The pathology of MS: new insights and potential clinical applications". The Neurologist. 13 (2): 45–56. doi:10.1097/01.nrl.0000253065.31662.37. PMID 17351524. S2CID 2993523.
Huang X, Hussain B, Chang J (January 2021). "Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms". CNS Neuroscience & Therapeutics. 27 (1): 36–47. doi:10.1111/cns.13569. PMC 7804893. PMID 33381913.
Ferré JC, Shiroishi MS, Law M (November 2012). "Advanced techniques using contrast media in neuroimaging". Magnetic Resonance Imaging Clinics of North America. 20 (4): 699–713. doi:10.1016/j.mric.2012.07.007. PMC 3479680. PMID 23088946.
Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. (June 2019). "Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 90 (6): 642–651. doi:10.1136/jnnp-2018-320050. PMC 6581095. PMID 30683707.
Ellison PM, Goodall S, Kennedy N, Dawes H, Clark A, Pomeroy V, et al. (September 2022). "Neurostructural and Neurophysiological Correlates of Multiple Sclerosis Physical Fatigue: Systematic Review and Meta-Analysis of Cross-Sectional Studies". Neuropsychology Review. 32 (3): 506–519. doi:10.1007/s11065-021-09508-1. PMC 9381450. PMID 33961198.
Newland P, Starkweather A, Sorenson M (2016). "Central fatigue in multiple sclerosis: A review of the literature". The Journal of Spinal Cord Medicine. 39 (4): 386–399. doi:10.1080/10790268.2016.1168587. PMC 5102292. PMID 27146427.
Davis SL, Jay O, Wilson TE (2018). "Thermoregulatory dysfunction in multiple sclerosis". In Romanovsky AA (ed.). Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part II. Handbook of Clinical Neurology. Vol. 157. pp. 701–714. doi:10.1016/B978-0-444-64074-1.00042-2. ISBN 978-0-444-64074-1. PMID 30459034.
Loy BD, Taylor RL, Fling BW, Horak FB (September 2017). "Relationship between perceived fatigue and performance fatigability in people with multiple sclerosis: A systematic review and meta-analysis". Journal of Psychosomatic Research. 100: 1–7. doi:10.1016/j.jpsychores.2017.06.017. PMC 5875709. PMID 28789787.
Trojano M, Paolicelli D (November 2001). "The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes". Neurological Sciences. 22 (Suppl 2): S98-102. doi:10.1007/s100720100044. PMID 11794488. S2CID 3057096.
Poser CM, Brinar VV (June 2004). "Diagnostic criteria for multiple sclerosis: an historical review". Clinical Neurology and Neurosurgery. 106 (3): 147–58. doi:10.1016/j.clineuro.2004.02.004. PMID 15177763. S2CID 23452341.
Montalban X, Lebrun-Frénay C, Oh J, Arrambide G, Moccia M, Pia Amato M, et al. (October 2025). "Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria". The Lancet Neurology. 24 (10): 850–865. doi:10.1016/S1474-4422(25)00270-4.
Rovira À (November 2017). "Diagnosis of Multiple Sclerosis". Journal of the Belgian Society of Radiology. 101 (S1): 12. doi:10.5334/jbr-btr.1426.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. (July 2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis". Annals of Neurology. 50 (1): 121–7. doi:10.1002/ana.1032. PMID 11456302. S2CID 13870943.
Rashid W, Miller DH (February 2008). "Recent advances in neuroimaging of multiple sclerosis". Seminars in Neurology. 28 (1): 46–55. doi:10.1055/s-2007-1019127. PMID 18256986. S2CID 260317568.
Sinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, et al. (MAGNIMS Study Group) (December 2019). "Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis". JAMA Neurology. 76 (12): 1446–1456. doi:10.1001/jamaneurol.2019.2478. PMC 6704746. PMID 31424490.
Castellaro M, Tamanti A, Pisani AI, Pizzini FB, Crescenzo F, Calabrese M (November 2020). "The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis". Diagnostics. 10 (12): 1025. doi:10.3390/diagnostics10121025. PMC 7760678. PMID 33260401.
Al-Zandi SH, Fayadh NA, Al-Waely NK (1 March 2018). "Central vein sign detected by SWI at 3 T MRI as a discriminator between multiple sclerosis and leukoaraiosis". The Egyptian Journal of Radiology and Nuclear Medicine. 49 (1): 158–164. doi:10.1016/j.ejrnm.2017.09.003.
Guisset F, Lolli V, Bugli C, Perrotta G, Absil J, Dachy B, et al. (June 2021). "The central vein sign in multiple sclerosis patients with vascular comorbidities". Multiple Sclerosis. 27 (7): 1057–1065. doi:10.1177/1352458520943785. hdl:2078.1/239849. PMID 32749948.
Weigel M, Dechent P, Galbusera R, Bahn E, Nair G, Lu PJ, et al. (July 2021). "Imaging multiple sclerosis pathology at 160 μm isotropic resolution by human whole-brain ex vivo magnetic resonance imaging at 3 T". Scientific Reports. 11 (1) 15491. doi:10.1038/s41598-021-94891-1. PMC 8322069. PMID 34326420.
Link H, Huang YM (November 2006). "Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness". Journal of Neuroimmunology. 180 (1–2): 17–28. doi:10.1016/j.jneuroim.2006.07.006. PMID 16945427. S2CID 22724352.
Solomon AJ (June 2019). "Diagnosis, Differential Diagnosis, and Misdiagnosis of Multiple Sclerosis". Continuum. 25 (3): 611–635. doi:10.1212/CON.0000000000000728. PMID 31162308. S2CID 173991777.
Lublin FD, et al. (15 July 2014). "Defining the clinical course of multiple sclerosis, The 2013 revisions". Neurology. 83 (3): 278–286. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.
Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ (June 2020). "The 2013 clinical course descriptors for multiple sclerosis: A clarification". Neurology. 94 (24): 1088–1092. doi:10.1212/WNL.0000000000009636. PMC 7455332. PMID 32471886.
Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (May 2005). "Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis". The Lancet. Neurology. 4 (5): 281–8. doi:10.1016/S1474-4422(05)70071-5. PMID 15847841. S2CID 36401666.
Miller DH, Leary SM (October 2007). "Primary-progressive multiple sclerosis". The Lancet. Neurology. 6 (10): 903–12. doi:10.1016/S1474-4422(07)70243-0. hdl:1871/24666. PMID 17884680. S2CID 31389841.
Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M (April 2006). "Secondary progressive multiple sclerosis: current knowledge and future challenges". The Lancet. Neurology. 5 (4): 343–54. doi:10.1016/S1474-4422(06)70410-0. PMID 16545751. S2CID 39503553.
Sørensen PS, Centonze D, Giovannoni G, et al. (2020). "Expert opinion on the use of cladribine tablets in clinical practice". Ther Adv Neurol Disord (Review). 13 1756286420935019. doi:10.1177/1756286420935019. PMC 7318823. PMID 32636933.
Pittock SJ, Rodriguez M (2008). "Benign Multiple Sclerosis: A Distinct Clinical Entity with Therapeutic Implications". In Rodriguez M (ed.). Advances in multiple Sclerosis and Experimental Demyelinating Diseases. Current Topics in Microbiology and Immunology. Vol. 318. pp. 1–17. doi:10.1007/978-3-540-73677-6_1. ISBN 978-3-540-73676-9. PMID 18219812.
Feinstein A (2007). "Chapter 1 - Multiple sclerosis: diagnosis and definitions". The Clinical Neuropsychiatry of Multiple Sclerosis. pp. 1–27. doi:10.1017/CBO9780511543760. ISBN 978-0-521-85234-0.
Stadelmann C, Brück W (November 2004). "Lessons from the neuropathology of atypical forms of multiple sclerosis". Neurological Sciences. 25 (Suppl 4): S319 – S322. doi:10.1007/s10072-004-0333-1. PMID 15727225. S2CID 21212935.
Fujihara K (June 2019). "Neuromyelitis optica spectrum disorders: still evolving and broadening". Current Opinion in Neurology (Review). 32 (3): 385–394. doi:10.1097/WCO.0000000000000694. PMC 6522202. PMID 30893099.
McGinley MP, Goldschmidt CH, Rae-Grant AD (February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765–779. doi:10.1001/jama.2020.26858. PMID 33620411. S2CID 232019589.
Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BA, Gronseth GS, et al. (April 2018). "Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology". Neurology. 90 (17): 777–788. doi:10.1212/WNL.0000000000005347. PMID 29686116.
Burton JM, O'Connor PW, Hohol M, Beyene J (December 2012). "Oral versus intravenous steroids for treatment of relapses in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2012 (12) CD006921. doi:10.1002/14651858.CD006921.pub3. PMC 12145957. PMID 23235634.
Filippini G, Brusaferri F, Sibley WA, et al. (2000). "Corticosteroids or ACTH for acute exacerbations in multiple sclerosis". Cochrane Database Syst Rev. 2013 (4) CD001331. doi:10.1002/14651858.CD001331. PMC 11391333. PMID 11034713.
Petzold A, Braithwaite T, van Oosten BW (January 2020). "Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence". J. Neurol. Neurosurg. Psychiatry (Review). 91 (1): 9–14. doi:10.1136/jnnp-2019-321653. PMC 6952848. PMID 31740484.
He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, et al. (March 2016). "Teriflunomide for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2016 (3) CD009882. doi:10.1002/14651858.CD009882.pub3. PMC 10493042. PMID 27003123.
Rice GP, Incorvaia B, Munari L, et al. (2001). "Interferon in relapsing-remitting multiple sclerosis". Cochrane Database Syst Rev. 2001 (4) CD002002. doi:10.1002/14651858.CD002002. PMC 7017973. PMID 11687131.
Hassan-Smith G, Douglas MR (November 2011). "Management and prognosis of multiple sclerosis". British Journal of Hospital Medicine. 72 (11): M174-6. doi:10.12968/hmed.2011.72.Sup11.M174. PMID 22082979.
Freedman MS (January 2011). "Long-term follow-up of clinical trials of multiple sclerosis therapies". Neurology. 76 (1 Suppl 1): S26-34. doi:10.1212/WNL.0b013e318205051d. PMID 21205679. S2CID 16929304.
Qizilbash N, Mendez I, Sanchez-de la Rosa R (January 2012). "Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis". Clinical Therapeutics. 34 (1): 159–176.e5. doi:10.1016/j.clinthera.2011.12.006. PMID 22284996.
Bates D (January 2011). "Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials". Neurology. 76 (1 Suppl 1): S14-25. doi:10.1212/WNL.0b013e3182050388. PMID 21205678. S2CID 362182.
Clerico M, Faggiano F, Palace J, et al. (April 2008). "Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis". Cochrane Database Syst Rev (2) CD005278. doi:10.1002/14651858.CD005278.pub3. PMID 18425915.
Johnston J, So TY (June 2012). "First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview". Drugs. 72 (9): 1195–211. doi:10.2165/11634010-000000000-00000. PMID 22642799. S2CID 20323687.
La Mantia L, Tramacere I, Firwana B, et al. (April 2016). "Fingolimod for relapsing-remitting multiple sclerosis". Cochrane Database Syst Rev. 2016 (4) CD009371. doi:10.1002/14651858.CD009371.pub2. PMC 10401910. PMID 27091121.
Xu Z, Zhang F, Sun F, et al. (April 2015). "Dimethyl fumarate for multiple sclerosis". Cochrane Database Syst Rev. 2015 (4) CD011076. doi:10.1002/14651858.CD011076.pub2. PMC 10663978. PMID 25900414.
Killestein J, Rudick RA, Polman CH (November 2011). "Oral treatment for multiple sclerosis". The Lancet. Neurology. 10 (11): 1026–34. doi:10.1016/S1474-4422(11)70228-9. PMID 22014437. S2CID 206160178.
Filippini G, Del Giovane C, Clerico M, et al. (April 2017). "Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis". Cochrane Database Syst Rev. 2017 (4) CD012200. doi:10.1002/14651858.CD012200.pub2. PMC 6478290. PMID 28440858.
Filippini G, Del Giovane C, Vacchi L, et al. (June 2013). "Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis". Cochrane Database Syst Rev (6) CD008933. doi:10.1002/14651858.CD008933.pub2. PMC 11627144. PMID 23744561.
La Mantia L, Di Pietrantonj C, Rovaris M, et al. (November 2016). "Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis". Cochrane Database Syst Rev. 2016 (11) CD009333. doi:10.1002/14651858.CD009333.pub3. PMC 6464642. PMID 27880972.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, Del Giovane C, Peryer G, Piggott T, et al. (January 2024). "Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis". Cochrane Database Syst Rev. 2024 (1) CD011381. doi:10.1002/14651858.CD011381.pub3. PMC 10765473. PMID 38174776.
Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G (May 2013). "Mitoxantrone for multiple sclerosis". The Cochrane Database of Systematic Reviews. 5 (5) CD002127. doi:10.1002/14651858.CD002127.pub3. hdl:2434/533488. PMC 11745300. PMID 23728638.
Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW (May 2010). "Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (18): 1463–70. doi:10.1212/WNL.0b013e3181dc1ae0. PMC 2871006. PMID 20439849.
Faissner S, Gold R (2019). "Progressive multiple sclerosis: latest therapeutic developments and future directions". Therapeutic Advances in Neurological Disorders. 12 1756286419878323. doi:10.1177/1756286419878323. PMC 6764045. PMID 31598138.
Lin M, Zhang J, Zhang Y, Luo J, Shi S, et al. (Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group) (May 2022). "Ocrelizumab for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2022 (5) CD013247. doi:10.1002/14651858.CD013247.pub2. PMC 9115862. PMID 35583174.
Balak DM, Hengstman GJ, Çakmak A, Thio HB (December 2012). "Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review". Multiple Sclerosis. 18 (12): 1705–17. doi:10.1177/1352458512438239. hdl:1765/73097. PMID 22371220.
La Mantia L, Munari LM, Lovati R (May 2010). "Glatiramer acetate for multiple sclerosis". The Cochrane Database of Systematic Reviews (5) CD004678. doi:10.1002/14651858.CD004678.pub2. PMID 20464733.
Tremlett H, Oger J (November 2004). "Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis". Journal of Neurology. 251 (11): 1297–303. doi:10.1007/s00415-004-0619-5. PMID 15592724. S2CID 12529733.
Comi G (October 2009). "Treatment of multiple sclerosis: role of natalizumab". Neurological Sciences. 30. 30 (S2): S155-8. doi:10.1007/s10072-009-0147-2. PMID 19882365. S2CID 25910077.
Hunt D, Giovannoni G (February 2012). "Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring". Practical Neurology. 12 (1): 25–35. doi:10.1136/practneurol-2011-000092. PMID 22258169. S2CID 46326042.
Kesselring J, Beer S (October 2005). "Symptomatic therapy and neurorehabilitation in multiple sclerosis". The Lancet. Neurology. 4 (10): 643–52. doi:10.1016/S1474-4422(05)70193-9. PMID 16168933. S2CID 28253186.
Khan F, Turner-Stokes L, Ng L, Kilpatrick T (April 2007). Khan F (ed.). "Multidisciplinary rehabilitation for adults with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2011 (2) CD006036. doi:10.1002/14651858.CD006036.pub2. PMC 8992048. PMID 17443610.
Köpke S, Solari A, Rahn A, Khan F, Heesen C, Giordano A (October 2018). "Information provision for people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2018 (10) CD008757. doi:10.1002/14651858.CD008757.pub3. PMC 6517040. PMID 30317542.
Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH (May 2005). "Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews". Clinical Rehabilitation. 19 (3): 247–54. doi:10.1191/0269215505cr870oa. hdl:1871/26505. PMID 15859525.
Steultjens EM, Dekker J, Bouter LM, Cardol M, Van de Nes JC, Van den Ende CH (2003). Steultjens EE (ed.). "Occupational therapy for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2010 (3) CD003608. doi:10.1002/14651858.CD003608. PMC 9022193. PMID 12917976.
Amatya B, Khan F, Galea M (January 2019). "Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews". The Cochrane Database of Systematic Reviews. 1 (1) CD012732. doi:10.1002/14651858.CD012732.pub2. PMC 6353175. PMID 30637728.
Heine M, van de Port I, Rietberg MB, van Wegen EE, Kwakkel G (September 2015). "Exercise therapy for fatigue in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2015 (9) CD009956. doi:10.1002/14651858.CD009956.pub2. PMC 9554249. PMID 26358158.
Gallien P, Nicolas B, Robineau S, Pétrilli S, Houedakor J, Durufle A (July 2007). "Physical training and multiple sclerosis". Annales de Réadaptation et de Médecine Physique. 50 (6): 373–6, 369–72. doi:10.1016/j.annrmp.2007.04.004. PMID 17482708.
Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G (January 2005). Kwakkel G (ed.). "Exercise therapy for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2005 (1) CD003980. doi:10.1002/14651858.CD003980.pub2. PMC 6485797. PMID 15674920.
Thomas PW, Thomas S, Hillier C, Galvin K, Baker R (January 2006). Thomas PW (ed.). "Psychological interventions for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2010 (1) CD004431. doi:10.1002/14651858.CD004431.pub2. PMC 8406851. PMID 16437487.
Rosti-Otajärvi EM, Hämäläinen PI (February 2014). "Neuropsychological rehabilitation for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2014 (2) CD009131. doi:10.1002/14651858.CD009131.pub3. PMC 10966661. PMID 24515630.
Latorraca CO, Martimbianco AL, Pachito DV, Torloni MR, Pacheco RL, Pereira JG, et al. (October 2019). "Palliative care interventions for people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2019 (10) CD012936. doi:10.1002/14651858.CD012936.pub2. PMC 6803560. PMID 31637711.
Hayes S, Galvin R, Kennedy C, Finlayson M, McGuigan C, Walsh CD, et al. (November 2019). "Interventions for preventing falls in people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2019 (11) CD012475. doi:10.1002/14651858.CD012475.pub2. PMC 6953359. PMID 31778221.
van den Akker LE, Beckerman H, Collette EH, Eijssen IC, Dekker J, de Groot V (November 2016). "Effectiveness of cognitive behavioral therapy for the treatment of fatigue in patients with multiple sclerosis: A systematic review and meta-analysis". Journal of Psychosomatic Research. 90: 33–42. doi:10.1016/j.jpsychores.2016.09.002. PMID 27772557.
Amatya B, Young J, Khan F (December 2018). "Non-pharmacological interventions for chronic pain in multiple sclerosis". The Cochrane Database of Systematic Reviews. 12 (12) CD012622. doi:10.1002/14651858.CD012622.pub2. PMC 6516893. PMID 30567012.
Corvillo I, Varela E, Armijo F, Alvarez-Badillo A, Armijo O, Maraver F (December 2017). "Efficacy of aquatic therapy for multiple sclerosis: a systematic review". Eur J Phys Rehabil Med (Review). 53 (6): 944–952. doi:10.23736/S1973-9087.17.04570-1. PMID 28215060.
Khan F, Amatya B, Bensmail D, Yelnik A (July 2019). "Non-pharmacological interventions for spasticity in adults: An overview of systematic reviews". Ann Phys Rehabil Med. 62 (4): 265–273. doi:10.1016/j.rehab.2017.10.001. PMID 29042299. S2CID 207497395.
Etoom M, Khraiwesh Y, Lena F, et al. (November 2018). "Effectiveness of Physiotherapy Interventions on Spasticity in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis". Am J Phys Med Rehabil. 97 (11): 793–807. doi:10.1097/PHM.0000000000000970. PMID 29794531. S2CID 44156766.
Olsen SA (2009). "A review of complementary and alternative medicine (CAM) by people with multiple sclerosis". Occupational Therapy International. 16 (1): 57–70. doi:10.1002/oti.266. PMID 19222053.
Parks NE, Jackson-Tarlton CS, Vacchi L, Merdad R, Johnston BC (May 2020). "Dietary interventions for multiple sclerosis-related outcomes". The Cochrane Database of Systematic Reviews. 2020 (5) CD004192. doi:10.1002/14651858.CD004192.pub4. PMC 7388136. PMID 32428983.
Grigorian A, Araujo L, Naidu NN, Place DJ, Choudhury B, Demetriou M (November 2011). "N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis". The Journal of Biological Chemistry. 286 (46): 40133–41. doi:10.1074/jbc.M111.277814. PMC 3220534. PMID 21965673.
Pozuelo-Moyano B, Benito-León J, Mitchell AJ, Hernández-Gallego J (2013). "A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis". Neuroepidemiology (Systematic review). 40 (3): 147–53. doi:10.1159/000345122. PMC 3649517. PMID 23257784. the available evidence substantiates neither clinically significant benefit nor harm from vitamin D in the treatment of patients with MS
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E (October 2006). "Cannabis use in patients with multiple sclerosis". Multiple Sclerosis. 12 (5): 646–51. doi:10.1177/1352458506070947. PMID 17086912. S2CID 34692470.
Torres-Moreno MC, Papaseit E, Torrens M, Farré M (October 2018). "Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis". JAMA Network Open. 1 (6): e183485. doi:10.1001/jamanetworkopen.2018.3485. PMC 6324456. PMID 30646241.
Bennett M, Heard R (2004). Bennett MH (ed.). "Hyperbaric oxygen therapy for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2011 (1) CD003057. doi:10.1002/14651858.CD003057.pub2. PMC 8407327. PMID 14974004.
Simpson R, Booth J, Lawrence M, Byrne S, Mair F, Mercer S (January 2014). "Mindfulness based interventions in multiple sclerosis—a systematic review". BMC Neurology. 14 15. doi:10.1186/1471-2377-14-15. PMC 3900731. PMID 24438384.
Jagannath VA, Filippini G, Di Pietrantonj C, Asokan GV, Robak EW, Whamond L, et al. (September 2018). "Vitamin D for the management of multiple sclerosis". The Cochrane Database of Systematic Reviews. 9 (9) CD008422. doi:10.1002/14651858.CD008422.pub3. PMC 6513642. PMID 30246874.
Motte J, Gold R (December 2020). "High-dose biotin in multiple sclerosis: the end of the road". Lancet Neurol. 19 (12): 965–966. doi:10.1016/S1474-4422(20)30353-7. PMID 33222766. S2CID 225049079.
Tryfonos C, Mantzorou M, Fotiou D, Vrizas M, Vadikolias K, Pavlidou E, et al. (September 2019). "Dietary Supplements on Controlling Multiple Sclerosis Symptoms and Relapses: Current Clinical Evidence and Future Perspectives". Medicines. 6 (3): 95. doi:10.3390/medicines6030095. PMC 6789617. PMID 31547410.
Sedel F, Bernard D, Mock DM, Tourbah A (November 2016). "Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis". Neuropharmacology. 110 (Pt B): 644–653. doi:10.1016/j.neuropharm.2015.08.028. PMID 26327679.
Goldschmidt CH, Cohen JA (July 2020). "The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis". Neurotherapeutics. 17 (3): 968–970. doi:10.1007/s13311-020-00907-5. PMC 7609671. PMID 32761325.
Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K (May 2022). "Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 5 (5) CD013444. doi:10.1002/14651858.CD013444.pub2. PMC 9069991. PMID 35510826.
Cree BA, Hartung HP, Barnett M (June 2022). "New drugs for multiple sclerosis: new treatment algorithms". Curr Opin Neurol. 35 (3): 262–270. doi:10.1097/WCO.0000000000001063. PMID 35674067. S2CID 249438715.
Oh J, Vidal-Jordana A, Montalban X (December 2018). "Multiple sclerosis: clinical aspects". Curr Opin Neurol. 31 (6): 752–759. doi:10.1097/WCO.0000000000000622. PMID 30300239. Archived from the original on 25 November 2024. Retrieved 2 June 2024.
Hauser SL, Cree BA (December 2020). "Treatment of Multiple Sclerosis: A Review". Am J Med. 133 (12): 1380–1390.e2. doi:10.1016/j.amjmed.2020.05.049. PMC 7704606. PMID 32682869.
Ontaneda D (June 2019). "Progressive Multiple Sclerosis". Continuum. 25 (3): 736–752. doi:10.1212/CON.0000000000000727. PMID 31162314. S2CID 174808956.
Inojosa H, Proschmann U, Akgün K, Ziemssen T (April 2021). "A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition". J Neurol. 268 (4): 1210–1221. doi:10.1007/s00415-019-09489-5. PMID 31363847. S2CID 198999832. Expanded Disability Status Scale (EDSS) 6.0 is equivalent to requiring a walking aid, and EDSS 8.0 equivalent to chair or bedbound
Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (April 2018). "Multiple sclerosis". Lancet. 391 (10130): 1622–1636. doi:10.1016/S0140-6736(18)30481-1. PMID 29576504. S2CID 4313310.
Lunde HM, Assmus J, Myhr KM, Bø L, Grytten N (August 2017). "Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (8): 621–625. doi:10.1136/jnnp-2016-315238. PMC 5537547. PMID 28365589.
Kurtzke JF (October 1993). "Epidemiologic evidence for multiple sclerosis as an infection". Clinical Microbiology Reviews. 6 (4): 382–427. doi:10.1128/CMR.6.4.382. PMC 358295. PMID 8269393.
Alonso A, Hernán MA (July 2008). "Temporal trends in the incidence of multiple sclerosis: a systematic review". Neurology. 71 (2): 129–135. doi:10.1212/01.wnl.0000316802.35974.34. PMC 4109189. PMID 18606967.
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. (December 2020). "Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition". Multiple Sclerosis. 26 (14): 1816–1821. doi:10.1177/1352458520970841. PMC 7720355. PMID 33174475.
Compston A (October 1988). "The 150th anniversary of the first depiction of the lesions of multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 51 (10): 1249–52. doi:10.1136/jnnp.51.10.1249. PMC 1032909. PMID 3066846.
Lassmann H (October 1999). "The pathology of multiple sclerosis and its evolution". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354 (1390): 1635–40. doi:10.1098/rstb.1999.0508. PMC 1692680. PMID 10603616.
Lassmann H (July 2005). "Multiple sclerosis pathology: evolution of pathogenetic concepts". Brain Pathology. 15 (3): 217–22. doi:10.1111/j.1750-3639.2005.tb00523.x. PMC 8095927. PMID 16196388. S2CID 8342303.
Milo R, Miller A (April 2014). "Revised diagnostic criteria of multiple sclerosis". Autoimmunity Reviews. 13 (4–5): 518–524. doi:10.1016/j.autrev.2014.01.012. PMID 24424194.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. (February 2011). "Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria". Annals of Neurology. 69 (2): 292–302. doi:10.1002/ana.22366. PMC 3084507. PMID 21387374.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. (July 2014). "Defining the clinical course of multiple sclerosis: the 2013 revisions". Neurology. 83 (3): 278–86. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.
Sørensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, et al. (24 June 2020). "Expert opinion on the use of cladribine tablets in clinical practice". Therapeutic Advances in Neurological Disorders. 13 1756286420935019. doi:10.1177/1756286420935019. PMC 7318823. PMID 32636933.
Medaer R (September 1979). "Does the history of multiple sclerosis go back as far as the 14th century?". Acta Neurologica Scandinavica. 60 (3): 189–92. doi:10.1111/j.1600-0447.1979.tb08970.x. PMID 390966. S2CID 221422840.
Holmøy T (2006). "A Norse contribution to the history of neurological diseases". European Neurology. 55 (1): 57–8. doi:10.1159/000091431. PMID 16479124.
Pearce JM (2005). "Historical descriptions of multiple sclerosis". European Neurology. 54 (1): 49–53. doi:10.1159/000087387. PMID 16103678.
Petzold A (2013). "Optic Neuritis: Another Dickensian Diagnosis". Neuro-Ophthalmology. 37 (6): 247–250. doi:10.3109/01658107.2013.830313. PMC 5291069. PMID 28167994.
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, et al. (March 2020). "Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies". Trends in Molecular Medicine. 26 (3): 296–310. doi:10.1016/j.molmed.2019.11.003. PMC 7106557. PMID 31862243.
DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A (June 2006). "Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up". Archives of Neurology. 63 (6): 839–844. doi:10.1001/archneur.63.6.noc50328. PMID 16606758.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. (January 2017). "Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis". The New England Journal of Medicine. 376 (3): 221–234. doi:10.1056/NEJMoa1601277. hdl:2445/178507. PMID 28002679. S2CID 205099904.
Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. (March 2022). "Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM". Nature. 603 (7900): 321–327. Bibcode:2022Natur.603..321L. doi:10.1038/s41586-022-04432-7. PMC 9382663. PMID 35073561.
Morandi E, Tanasescu R, Tarlinton RE, Constantinescu CS, Zhang W, Tench C, et al. (16 February 2017). Ruprecht K (ed.). "The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis". PLOS ONE. 12 (2) e0172415. Bibcode:2017PLoSO..1272415M. doi:10.1371/journal.pone.0172415. PMC 5313176. PMID 28207850.
Li Y, Fan T, Cui J (March 2022). "Human endogenous retroviruses in viral disease and therapy". Clinical and Translational Discovery. 2 (1) e38. doi:10.1002/ctd2.38. S2CID 247750447.
Rangel SC, da Silva MD, da Silva AL, Dos Santos JM, Neves LM, Pedrosa A, et al. (23 November 2022). "Human endogenous retroviruses and the inflammatory response: A vicious circle associated with health and illness". Frontiers in Immunology. 13 1057791. doi:10.3389/fimmu.2022.1057791. PMC 9744114. PMID 36518758.
Yang C, Hao Z, Zhang L, Zeng L, Wen J (October 2015). "Sodium channel blockers for neuroprotection in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2015 (10) CD010422. doi:10.1002/14651858.CD010422.pub2. PMC 9242538. PMID 26486929.
Misu T, Fujihara K (February 2019). "Neuromyelitis optica spectrum and myelin oligodendrocyte glycoprotein antibody-related disseminated encephalomyelitis". Clinical and Experimental Neuroimmunology. 10 (1): 9–17. doi:10.1111/cen3.12491.
Kira JI, Yamasaki R, Ogata H (2019). "Anti-neurofascin autoantibody and demyelination". Neurochemistry International. 130 104360. doi:10.1016/j.neuint.2018.12.011. PMID 30582947.
Popescu BF, Pirko I, Lucchinetti CF (August 2013). "Pathology of multiple sclerosis: where do we stand?". Continuum. 19 (4 Multiple Sclerosis): 901–21. doi:10.1212/01.CON.0000433291.23091.65. PMC 3915566. PMID 23917093.
Mehta V, Pei W, Yang G, Li S, Swamy E, Boster A, et al. (2013). "Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions". PLOS ONE. 8 (3) e57573. Bibcode:2013PLoSO...857573M. doi:10.1371/journal.pone.0057573. PMC 3597727. PMID 23516409.
Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. (October 2018). "Neurofilaments as biomarkers in neurological disorders". Nature Reviews. Neurology. 14 (10): 577–589. doi:10.1038/s41582-018-0058-z. PMID 30171200.
Petzold A (June 2005). "Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss". Journal of the Neurological Sciences. 233 (1–2): 183–98. doi:10.1016/j.jns.2005.03.015. PMID 15896809.
Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, et al. (December 2011). "Magnetic resonance techniques in multiple sclerosis: the present and the future". Archives of Neurology. 68 (12): 1514–20. doi:10.1001/archneurol.2011.914. hdl:11365/20521. PMID 22159052.
Swanberg KM, Landheer K, Pitt D, Juchem C (2019). "Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker". Frontiers in Neurology. 10 1173. doi:10.3389/fneur.2019.01173. PMC 6876616. PMID 31803127.
Moghadasi AN, Mirmosayyeb O, Barzegar M, Sahraian MA, Ghajarzadeh M (August 2021). "The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis". Neurol Sci. 42 (8): 3093–3099. doi:10.1007/s10072-021-05373-1. PMC 8184129. PMID 34100130.
Neumann B, Baror R, Zhao C, Segel M, Dietmann S, Rawji KS, et al. (October 2019). "Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells". Cell Stem Cell. 25 (4): 473–485.e8. doi:10.1016/j.stem.2019.08.015. PMC 6863391. PMID 31585093.
Gilbert EA, Livingston J, Flores EG, Khan M, Kandavel H, Morshead CM (January 2024). "Metformin treatment reduces inflammation, dysmyelination and disease severity in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis". Brain Research. 1822 148648. doi:10.1016/j.brainres.2023.148648. PMID 37890574.
De Keersmaecker AV, Van Doninck E, Popescu V, Willem L, Cambron M, Laureys G, et al. (21 February 2024). "A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial". Frontiers in Immunology. 15 1362629. doi:10.3389/fimmu.2024.1362629. PMC 11046490. PMID 38680485.
Wasko NJ, Nichols F, Clark RB (January 2020). "Multiple sclerosis, the microbiome, TLR2, and the hygiene hypothesis". Autoimmunity Reviews. 19 (1) 102430. doi:10.1016/j.autrev.2019.102430. PMID 31734400.
Aranow C (August 2011). "Vitamin D and the immune system". Journal of Investigative Medicine. 59 (6): 881–886. doi:10.2310/jim.0b013e31821b8755. PMC 3166406. PMID 21527855.
Tada T, Takemori T, Okumura K, Nonaka M, Tokuhisa T (February 1978). "Two distinct types of helper T cells involved in the secondary antibody response: independent and synergistic effects of Ia- and Ia+ helper T cells". The Journal of Experimental Medicine. 147 (2): 446–458. doi:10.1084/jem.147.2.446. PMC 2184496. PMID 415110.
Lassmann H (March 2018). "Multiple Sclerosis Pathology". Cold Spring Harbor Perspectives in Medicine. 8 (3) a028936. doi:10.1101/cshperspect.a028936. PMC 5830904. PMID 29358320.
Minagar A, Shapshak P, Alexander JS (28 December 2004). "Pathogenesis of HIV-Associated Dementia and Multiple Sclerosis: Role of Microglia and Astrocytes". In Aschner M, Costa LG (eds.). The Role of Glia in Neurotoxicity (2nd ed.). CRC Press. pp. 283–298. doi:10.1201/9781420039740-21. ISBN 978-0-429-12860-8.
Allentoft ME, Sikora M, Refoyo-Martínez A, Irving-Pease EK, Fischer A, Barrie W, et al. (11 January 2024). "Population genomics of post-glacial western Eurasia". Nature. 625 (7994): 301–311. Bibcode:2024Natur.625..301A. doi:10.1038/s41586-023-06865-0. PMC 10781627. PMID 38200295.
Barrie W, Yang Y, Irving-Pease E, Attfield KE, Scorrano G, Jensen LT, et al. (6 October 2023). "Elevated genetic risk for multiple sclerosis originated in Steppe Pastoralist populations". bioRxiv 10.1101/2023.10.06.561165. Our findings also support the interpretation of increased pathogen pressure as a driver of positive selection on immunogenetic variants associated with risk of the autoimmune disease multiple sclerosis in Steppe populations around 5,000 years ago[59]

fda.gov (Global: 447^th place; English: 338^th place)

accessdata.fda.gov

"BLA Approval Letter" (PDF). FDA. 28 March 2017. Archived from the original (PDF) on 2 April 2017.
"NDA 204063 – FDA Approved Labeling Text" (PDF). US Food and Drug Agency. 27 March 2013. Archived (PDF) from the original on 4 October 2013. Retrieved 5 April 2013.
"NDA Approval" (PDF). US Food and Drug Agency. 27 March 2013. Archived from the original (PDF) on 4 October 2013. Retrieved 5 April 2013.

gene.com (Global: low place; English: low place)

"FDA Approves Ocrevus Zunovo as the First and Only Twice-A-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis". Genentech (Press release). 13 September 2024. Archived from the original on 14 September 2024. Retrieved 13 September 2024.

globenewswire.com (Global: 2,614^th place; English: 1,549^th place)

"TG Therapeutics Announces FDA Approval of Briumvi (ublituximab-xiiy)" (Press release). TG Therapeutics. 28 December 2022. Archived from the original on 28 December 2022. Retrieved 29 December 2022 – via GlobeNewswire.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

Quinn É, Hynes SM (July 2021). "Occupational therapy interventions for multiple sclerosis: A scoping review". Scandinavian Journal of Occupational Therapy. 28 (5): 399–414. doi:10.1080/11038128.2020.1786160. hdl:10379/16066. PMID 32643486. S2CID 220436640.
Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, et al. (December 2022). "Diagnosis and classification of optic neuritis". The Lancet. Neurology. 21 (12): 1120–1134. doi:10.1016/s1474-4422(22)00200-9. hdl:2078.1/276419. PMID 36179757.
World Health Organization (2008). Atlas: Multiple Sclerosis Resources in the World 2008. Geneva: World Health Organization. pp. 15–16. hdl:10665/43968. ISBN 978-92-4-156375-8.
Guisset F, Lolli V, Bugli C, Perrotta G, Absil J, Dachy B, et al. (June 2021). "The central vein sign in multiple sclerosis patients with vascular comorbidities". Multiple Sclerosis. 27 (7): 1057–1065. doi:10.1177/1352458520943785. hdl:2078.1/239849. PMID 32749948.
Miller DH, Leary SM (October 2007). "Primary-progressive multiple sclerosis". The Lancet. Neurology. 6 (10): 903–12. doi:10.1016/S1474-4422(07)70243-0. hdl:1871/24666. PMID 17884680. S2CID 31389841.
Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G (May 2013). "Mitoxantrone for multiple sclerosis". The Cochrane Database of Systematic Reviews. 5 (5) CD002127. doi:10.1002/14651858.CD002127.pub3. hdl:2434/533488. PMC 11745300. PMID 23728638.
Balak DM, Hengstman GJ, Çakmak A, Thio HB (December 2012). "Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review". Multiple Sclerosis. 18 (12): 1705–17. doi:10.1177/1352458512438239. hdl:1765/73097. PMID 22371220.
Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH (May 2005). "Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews". Clinical Rehabilitation. 19 (3): 247–54. doi:10.1191/0269215505cr870oa. hdl:1871/26505. PMID 15859525.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. (January 2017). "Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis". The New England Journal of Medicine. 376 (3): 221–234. doi:10.1056/NEJMoa1601277. hdl:2445/178507. PMID 28002679. S2CID 205099904.
Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, et al. (December 2011). "Magnetic resonance techniques in multiple sclerosis: the present and the future". Archives of Neurology. 68 (12): 1514–20. doi:10.1001/archneurol.2011.914. hdl:11365/20521. PMID 22159052.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Mazumder R, Murchison C, Bourdette D, Cameron M (25 September 2014). "Falls in people with multiple sclerosis compared with falls in healthy controls". PLOS ONE. 9 (9) e107620. Bibcode:2014PLoSO...9j7620M. doi:10.1371/journal.pone.0107620. PMC 4177842. PMID 25254633.
Berer K, Krishnamoorthy G (November 2014). "Microbial view of central nervous system autoimmunity". FEBS Letters. 588 (22): 4207–13. Bibcode:2014FEBSL.588.4207B. doi:10.1016/j.febslet.2014.04.007. PMID 24746689. S2CID 2772656.
Hassani A, Corboy JR, Al-Salam S, Khan G (2018). "Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells". PLOS ONE. 13 (2) e0192109. Bibcode:2018PLoSO..1392109H. doi:10.1371/journal.pone.0192109. PMC 5796799. PMID 29394264.
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (January 2022). "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis". Science. 375 (6578): 296–301. Bibcode:2022Sci...375..296B. doi:10.1126/science.abj8222. PMID 35025605. S2CID 245983763. See lay summary: Gallagher J (13 April 2022). "Is a virus we all have causing multiple sclerosis?". BBC. Archived from the original on 25 April 2022. Retrieved 14 April 2022.
Vitturi BK, Montecucco A, Rahmani A, Dini G, Durando P (15 November 2023). "Occupational risk factors for multiple sclerosis: a systematic review with meta-analysis". Frontiers in Public Health. 11 (2023): Introduction, Results. Bibcode:2023FrPH...1185103V. doi:10.3389/fpubh.2023.1285103. PMC 10694508. PMID 38054069.
Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. (March 2022). "Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM". Nature. 603 (7900): 321–327. Bibcode:2022Natur.603..321L. doi:10.1038/s41586-022-04432-7. PMC 9382663. PMID 35073561.
Morandi E, Tanasescu R, Tarlinton RE, Constantinescu CS, Zhang W, Tench C, et al. (16 February 2017). Ruprecht K (ed.). "The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis". PLOS ONE. 12 (2) e0172415. Bibcode:2017PLoSO..1272415M. doi:10.1371/journal.pone.0172415. PMC 5313176. PMID 28207850.
Mehta V, Pei W, Yang G, Li S, Swamy E, Boster A, et al. (2013). "Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions". PLOS ONE. 8 (3) e57573. Bibcode:2013PLoSO...857573M. doi:10.1371/journal.pone.0057573. PMC 3597727. PMID 23516409.
Allentoft ME, Sikora M, Refoyo-Martínez A, Irving-Pease EK, Fischer A, Barrie W, et al. (11 January 2024). "Population genomics of post-glacial western Eurasia". Nature. 625 (7994): 301–311. Bibcode:2024Natur.625..301A. doi:10.1038/s41586-023-06865-0. PMC 10781627. PMID 38200295.

jamanetwork.com (Global: 2,650^th place; English: 3,409^th place)

McGinley MP, Goldschmidt CH, Rae-Grant AD (23 February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765. doi:10.1001/jama.2020.26858. ISSN 0098-7484.

msif.org (Global: low place; English: low place)

"Atlas of MS" (PDF). Multiple Sclerosis International Federation. September 2020.

mssociety.org.uk (Global: low place; English: low place)

"The McDonald criteria". MS Society UK. 31 May 2023. Archived from the original on 2 December 2024. Retrieved 26 November 2024.
"MS Symptoms and Signs of MS | MS Society". www.mssociety.org.uk. Retrieved 25 February 2025.
"Pregnancy, birth, breastfeeding and MS". Multiple Sclerosis Society. Archived from the original on 8 April 2024. Retrieved 8 April 2024.
"Can metformin and clemastine repair myelin in people with MS?". MS Society UK. Archived from the original on 30 July 2024. Retrieved 30 July 2024.
"Metformin". Multiple Sclerosis Society. Archived from the original on 30 July 2024. Retrieved 30 July 2024.

mstrust.org.uk (Global: low place; English: low place)

"Fatigue". Letchworth Garden City, United Kingdom: Multiple Sclerosis Trust. Archived from the original on 16 January 2024. Retrieved 16 January 2024.
"MS Decisions aid". Letchworth Garden City, United Kingdom: Multiple Sclerosis Trust. 3 December 2023. Archived from the original on 3 December 2023. Retrieved 3 December 2023.

multiplesclerosisnewstoday.com (Global: low place; English: low place)

Chapman M (16 June 2020). "$7.2M NIH Grant Supports Study of MS Diagnostic Biomarker". BioNews Services. Archived from the original on 5 October 2021. Retrieved 5 October 2021.

nationalmssociety.org (Global: low place; English: low place)

"Clinically Isolated Syndrome (CIS)". National MS Society. Archived from the original on 30 September 2023. Retrieved 4 October 2023.
"Novel Study Suggests that MS was Brought to Northern Europe 5,000 Years Ago". National MS Society. 10 January 2024. Archived from the original on 11 January 2024. Retrieved 11 January 2024.

nature.com (Global: 234^th place; English: 397^th place)

Olsson T, Barcellos LF, Alfredsson L (January 2017). "Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis". Nature Reviews Neurology. 13 (1): 25–36. doi:10.1038/nrneurol.2016.187. ISSN 1759-4766. PMID 27934854.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Compston A, Coles A (October 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–1517. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977. S2CID 195686659.
Milo R, Kahana E (March 2010). "Multiple sclerosis: geoepidemiology, genetics and the environment". Autoimmunity Reviews. 9 (5): A387-94. doi:10.1016/j.autrev.2009.11.010. PMID 19932200.
Nakahara J, Maeda M, Aiso S, Suzuki N (February 2012). "Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy". Clinical Reviews in Allergy & Immunology. 42 (1): 26–34. doi:10.1007/s12016-011-8287-6. PMID 22189514. S2CID 21058811.
Tsang BK, Macdonell R (December 2011). "Multiple sclerosis- diagnosis, management and prognosis". Australian Family Physician. 40 (12): 948–955. PMID 22146321.
Liu Z, Liao Q, Wen H, Zhang Y (June 2021). "Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis". Autoimmunity Reviews. 20 (6) 102826. doi:10.1016/j.autrev.2021.102826. PMID 33878488. S2CID 233325057.
Alphonsus KB, Su Y, D'Arcy C (April 2019). "The effect of exercise, yoga and physiotherapy on the quality of life of people with multiple sclerosis: Systematic review and meta-analysis". Complementary Therapies in Medicine. 43: 188–195. doi:10.1016/j.ctim.2019.02.010. PMID 30935529. S2CID 86669723.
Compston A, Coles A (April 2002). "Multiple sclerosis". Lancet. 359 (9313): 1221–1231. doi:10.1016/S0140-6736(02)08220-X. PMID 11955556. S2CID 14207583.
Piryonesi SM, Rostampour S, Piryonesi SA (April 2021). "Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms". Multiple Sclerosis and Related Disorders. 49 102740. doi:10.1016/j.msard.2021.102740. PMID 33450500. S2CID 231624230.
Mazumder R, Murchison C, Bourdette D, Cameron M (25 September 2014). "Falls in people with multiple sclerosis compared with falls in healthy controls". PLOS ONE. 9 (9) e107620. Bibcode:2014PLoSO...9j7620M. doi:10.1371/journal.pone.0107620. PMC 4177842. PMID 25254633.
Ford H (July 2020). "Clinical presentation and diagnosis of multiple sclerosis". Clinical Medicine. 20 (4). London, England: 380–383. doi:10.7861/clinmed.2020-0292. ISSN 1473-4893. PMC 7385797. PMID 32675142.
Baecher-Allan C, Kaskow BJ, Weiner HL (February 2018). "Multiple Sclerosis: Mechanisms and Immunotherapy". Neuron. 97 (4): 742–768. doi:10.1016/j.neuron.2018.01.021. PMID 29470968. S2CID 3499974.
^{[medical citation needed]}Lublin FD, Reingold SC (April 1996). "Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology. 46 (4): 907–911. doi:10.1212/WNL.46.4.907. PMID 8780061. S2CID 40213123.
Loma I, Heyman R (September 2011). "Multiple sclerosis: pathogenesis and treatment". Current Neuropharmacology. 9 (3): 409–416. doi:10.2174/157015911796557911. PMC 3151595. PMID 22379455.
Ward M, Goldman MD (August 2022). "Epidemiology and Pathophysiology of Multiple Sclerosis". Continuum. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. PMID 35938654. S2CID 251375096.
Aloisi F, Cross AH (October 2022). "MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis". Journal of Neuroimmunology. 371 577935. doi:10.1016/j.jneuroim.2022.577935. PMID 35931008. S2CID 251152784.
Ascherio A, Munger KL (April 2007). "Environmental risk factors for multiple sclerosis. Part I: the role of infection". Annals of Neurology. 61 (4): 288–299. doi:10.1002/ana.21117. PMID 17444504. S2CID 7682774.
McGinley MP, Goldschmidt CH, Rae-Grant AD (February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765–779. doi:10.1001/jama.2020.26858. PMID 33620411. S2CID 232019589.
Quinn É, Hynes SM (July 2021). "Occupational therapy interventions for multiple sclerosis: A scoping review". Scandinavian Journal of Occupational Therapy. 28 (5): 399–414. doi:10.1080/11038128.2020.1786160. hdl:10379/16066. PMID 32643486. S2CID 220436640.
Weinshenker BG (1994). "Natural history of multiple sclerosis". Annals of Neurology. 36 (Suppl): S6-11. doi:10.1002/ana.410360704. PMID 8017890. S2CID 7140070.
Wecker S, Freudenstein D, Ganser I, Angstwurm K, Lee DH, Linker RA (2024). "The impact of different lifestyle factors on disability in multiple sclerosis at older ages: a monocentric retrospective study". Therapeutic Advances in Neurological Disorders. 17 17562864241284166. doi:10.1177/17562864241284166. ISSN 1756-2856. PMC 11528639. PMID 39494114.
Dobson R, Giovannoni G (2019). "Multiple sclerosis – a review". European Journal of Neurology. 26 (1): 27–40. doi:10.1111/ene.13819. ISSN 1468-1331. PMID 30300457.
Berer K, Krishnamoorthy G (November 2014). "Microbial view of central nervous system autoimmunity". FEBS Letters. 588 (22): 4207–13. Bibcode:2014FEBSL.588.4207B. doi:10.1016/j.febslet.2014.04.007. PMID 24746689. S2CID 2772656.
Lane J, Ng HS, Poyser C, Lucas RM, Tremlett H (July 2022). "Multiple sclerosis incidence: A systematic review of change over time by geographical region". Mult Scler Relat Disord. 63 103932. doi:10.1016/j.msard.2022.103932. PMID 35667315. S2CID 249188137.
Dobson R, Giovannoni G (2019). "Multiple sclerosis – a review". European Journal of Neurology. 26 (1): 27–40. doi:10.1111/ene.13819. ISSN 1468-1331. PMID 30300457.
Clanet M (June 2008). "Jean-Martin Charcot. 1825 to 1893". International MS Journal. 15 (2): 59–61. PMID 18782501.
* Charcot J (1868). "Histologie de la sclerose en plaques". Gazette des Hopitaux, Paris. 41: 554–5.
Moore H, Nair KP, Baster K, Middleton R, Paling D, Sharrack B (August 2022). "Fatigue in multiple sclerosis: A UK MS-register based study". Multiple Sclerosis and Related Disorders. 64 103954. doi:10.1016/j.msard.2022.103954. PMID 35716477.
Bakalidou D, Giannopapas V, Giannopoulos S (July 2023). "Thoughts on Fatigue in Multiple Sclerosis Patients". Cureus. 15 (7) e42146. doi:10.7759/cureus.42146. PMC 10438195. PMID 37602098.
Plotas P, Nanousi V, Kantanis A, Tsiamaki E, Papadopoulos A, Tsapara A, et al. (July 2023). "Speech deficits in multiple sclerosis: a narrative review of the existing literature". European Journal of Medical Research. 28 (1) 252. doi:10.1186/s40001-023-01230-3. PMC 10364432. PMID 37488623.
Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, et al. (December 2022). "Diagnosis and classification of optic neuritis". The Lancet. Neurology. 21 (12): 1120–1134. doi:10.1016/s1474-4422(22)00200-9. hdl:2078.1/276419. PMID 36179757.
Cameron MH, Nilsagard Y (2018). "Balance, gait, and falls in multiple sclerosis". In Day BL, Lord SR (eds.). Balance, Gait, and Falls. Handbook of Clinical Neurology. Vol. 159. pp. 237–250. doi:10.1016/b978-0-444-63916-5.00015-x. ISBN 978-0-444-63916-5. PMID 30482317.
Ghasemi N, Razavi S, Nikzad E (January 2017). "Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy". Cell Journal. 19 (1): 1–10. doi:10.22074/cellj.2016.4867 (inactive 1 July 2025). PMC 5241505. PMID 28367411.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
Chen MH, Wylie GR, Sandroff BM, Dacosta-Aguayo R, DeLuca J, Genova HM (August 2020). "Neural mechanisms underlying state mental fatigue in multiple sclerosis: a pilot study". Journal of Neurology. 267 (8): 2372–2382. doi:10.1007/s00415-020-09853-w. PMID 32350648.
Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez MÁ, Meca-Lallana V, Ramió-Torrentà L (2019). "Cognitive Dysfunctions and Assessments in Multiple Sclerosis". Frontiers in Neurology. 10 581. doi:10.3389/fneur.2019.00581. PMC 6558141. PMID 31214113.
Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. (November 2018). "Recommendations for cognitive screening and management in multiple sclerosis care". Multiple Sclerosis. 24 (13): 1665–1680. doi:10.1177/1352458518803785. PMC 6238181. PMID 30303036.
Benedict RH, Amato MP, DeLuca J, Geurts JJ (October 2020). "Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues". The Lancet. Neurology. 19 (10): 860–871. doi:10.1016/S1474-4422(20)30277-5. PMC 10011205. PMID 32949546. S2CID 221744328.
Christogianni A, Bibb R, Davis SL, Jay O, Barnett M, Evangelou N, et al. (17 January 2018). "Temperature sensitivity in multiple sclerosis: An overview of its impact on sensory and cognitive symptoms". Temperature. 5 (3): 208–223. doi:10.1080/23328940.2018.1475831. PMC 6205043. PMID 30377640.
Kurtzke JF (November 1983). "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)". Neurology. 33 (11): 1444–52. doi:10.1212/WNL.33.11.1444. PMID 6685237.
Amato MP, Ponziani G (August 1999). "Quantification of impairment in MS: discussion of the scales in use". Multiple Sclerosis. 5 (4): 216–9. doi:10.1177/135245859900500404. PMID 10467378. S2CID 6763447.
Rudick RA, Cutter G, Reingold S (October 2002). "The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials". Multiple Sclerosis. 8 (5): 359–65. doi:10.1191/1352458502ms845oa. PMID 12356200. S2CID 31529508.
van Munster CE, Uitdehaag BM (March 2017). "Outcome Measures in Clinical Trials for Multiple Sclerosis". CNS Drugs. 31 (3): 217–236. doi:10.1007/s40263-017-0412-5. PMC 5336539. PMID 28185158.
Makhani N, Tremlett H (August 2021). "The multiple sclerosis prodrome". Nature Reviews. Neurology. 17 (8): 515–521. doi:10.1038/s41582-021-00519-3. PMC 8324569. PMID 34155379.
Marrie RA (December 2019). "Mounting evidence for a multiple sclerosis prodrome". Nature Reviews. Neurology. 15 (12): 689–690. doi:10.1038/s41582-019-0283-0. PMID 31654040. S2CID 204887642.
Tataru N, Vidal C, Decavel P, Berger E, Rumbach L (2006). "Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis". Neuroepidemiology. 27 (1): 28–32. doi:10.1159/000094233. PMID 16804331. S2CID 20870484.
Heesen C, Mohr DC, Huitinga I, Bergh FT, Gaab J, Otte C, et al. (March 2007). "Stress regulation in multiple sclerosis: current issues and concepts". Multiple Sclerosis. 13 (2): 143–148. doi:10.1177/1352458506070772. PMID 17439878. S2CID 8262595.
Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S (February 2001). "Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group". The New England Journal of Medicine. 344 (5): 319–326. doi:10.1056/NEJM200102013440501. PMID 11172162.
Grimaldi L, Papeix C, Hamon Y, Buchard A, Moride Y, Benichou J, et al. (October 2023). "Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups". JAMA Neurology. 80 (10): 1098–1104. doi:10.1001/jamaneurol.2023.2968. PMC 10481324. PMID 37669073.
Martinelli V (2000). "Trauma, stress and multiple sclerosis". Neurological Sciences. 21 (4 Suppl 2): S849 – S852. doi:10.1007/s100720070024. PMID 11205361. S2CID 2376078.
Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA (April 2019). "UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines". Practical Neurology. 19 (2): 106–114. doi:10.1136/practneurol-2018-002060. PMID 30612100.
Varytė G, Zakarevičienė J, Ramašauskaitė D, Laužikienė D, Arlauskienė A (January 2020). "Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity". Medicina. 56 (2): 49. doi:10.3390/medicina56020049. PMC 7074401. PMID 31973138.
Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. (November 2007). "Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain". The Journal of Experimental Medicine. 204 (12): 2899–2912. doi:10.1084/jem.20071030. PMC 2118531. PMID 17984305.
Hassani A, Corboy JR, Al-Salam S, Khan G (2018). "Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells". PLOS ONE. 13 (2) e0192109. Bibcode:2018PLoSO..1392109H. doi:10.1371/journal.pone.0192109. PMC 5796799. PMID 29394264.
Lutterotti A, Hayward-Koennecke H, Sospedra M, Martin R (2021). "Antigen-Specific Immune Tolerance in Multiple Sclerosis-Promising Approaches and How to Bring Them to Patients". Frontiers in Immunology. 12 640935. doi:10.3389/fimmu.2021.640935. PMC 8019937. PMID 33828551.
Gilden DH (March 2005). "Infectious causes of multiple sclerosis". The Lancet. Neurology. 4 (3): 195–202. doi:10.1016/S1474-4422(05)01017-3. PMC 7129502. PMID 15721830.
Soldan SS, Lieberman PM (January 2023). "Epstein-Barr virus and multiple sclerosis". Nature Reviews. Microbiology. 21 (1): 51–64. doi:10.1038/s41579-022-00770-5. PMC 9362539. PMID 35931816.
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (January 2022). "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis". Science. 375 (6578): 296–301. Bibcode:2022Sci...375..296B. doi:10.1126/science.abj8222. PMID 35025605. S2CID 245983763. See lay summary: Gallagher J (13 April 2022). "Is a virus we all have causing multiple sclerosis?". BBC. Archived from the original on 25 April 2022. Retrieved 14 April 2022.
Münz C (May 2004). "Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target". The Journal of Experimental Medicine. 199 (10): 1301–1304. doi:10.1084/jem.20040730. PMC 2211815. PMID 15148332.
Miclea A, Bagnoud M, Chan A, Hoepner R (6 May 2020). "A Brief Review of the Effects of Vitamin D on Multiple Sclerosis". Frontiers in Immunology. 11 781. doi:10.3389/fimmu.2020.00781. PMC 7218089. PMID 32435244.
Dyment DA, Ebers GC, Sadovnick AD (February 2004). "Genetics of multiple sclerosis". The Lancet. Neurology. 3 (2): 104–10. CiteSeerX 10.1.1.334.1312. doi:10.1016/S1474-4422(03)00663-X. PMID 14747002. S2CID 16707321.
Skene NG, Grant SG (2016). "Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment". Frontiers in Neuroscience. 10: 16. doi:10.3389/fnins.2016.00016. PMC 4730103. PMID 26858593.
Hassan-Smith G, Douglas MR (October 2011). "Epidemiology and diagnosis of multiple sclerosis". British Journal of Hospital Medicine. 72 (10): M146-51. doi:10.12968/hmed.2011.72.Sup10.M146. PMID 22041658.
Rosati G (April 2001). "The prevalence of multiple sclerosis in the world: an update". Neurological Sciences. 22 (2): 117–39. doi:10.1007/s100720170011. PMID 11603614. S2CID 207051545.
Baranzini SE (June 2011). "Revealing the genetic basis of multiple sclerosis: are we there yet?". Current Opinion in Genetics & Development. 21 (3): 317–24. doi:10.1016/j.gde.2010.12.006. PMC 3105160. PMID 21247752.
International Multiple Sclerosis Genetics Consortium (2019). "Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility". Science. 365 (6460) eaav7188. doi:10.1126/science.aav7188. PMC 7241648. PMID 31604244.
Simpson S, Wang W, Otahal P, Blizzard L, van der Mei IA, Taylor BV (November 2019). "Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 90 (11): 1193–1200. doi:10.1136/jnnp-2018-320189. PMID 31217172.
Pugliatti M, Sotgiu S, Rosati G (July 2002). "The worldwide prevalence of multiple sclerosis". Clinical Neurology and Neurosurgery. 104 (3): 182–91. doi:10.1016/S0303-8467(02)00036-7. PMID 12127652. S2CID 862001.
Grimaldi LM, Salemi G, Grimaldi G, Rizzo A, Marziolo R, Lo Presti C, et al. (November 2001). "High incidence and increasing prevalence of MS in Enna (Sicily), southern Italy". Neurology. 57 (10): 1891–3. doi:10.1212/wnl.57.10.1891. PMID 11723283. S2CID 34895995.
Marrie RA (December 2004). "Environmental risk factors in multiple sclerosis aetiology". The Lancet. Neurology. 3 (12): 709–18. doi:10.1016/S1474-4422(04)00933-0. PMID 15556803. S2CID 175786.
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009). "Vitamin D: an evidence-based review". Journal of the American Board of Family Medicine. 22 (6): 698–706. doi:10.3122/jabfm.2009.06.090037. PMID 19897699.
Sintzel MB, Rametta M, Reder AT (1 June 2018). "Vitamin D and Multiple Sclerosis: A Comprehensive Review". Neurology and Therapy. 7 (1): 59–85. doi:10.1007/s40120-017-0086-4. ISSN 2193-6536. PMC 5990512. PMID 29243029.
Olsson T, Barcellos LF, Alfredsson L (January 2017). "Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis". Nature Reviews Neurology. 13 (1): 25–36. doi:10.1038/nrneurol.2016.187. ISSN 1759-4766. PMID 27934854.
Vitturi BK, Montecucco A, Rahmani A, Dini G, Durando P (15 November 2023). "Occupational risk factors for multiple sclerosis: a systematic review with meta-analysis". Frontiers in Public Health. 11 (2023): Introduction, Results. Bibcode:2023FrPH...1185103V. doi:10.3389/fpubh.2023.1285103. PMC 10694508. PMID 38054069.
Stowe J, Andrews N, Miller E (January 2020). "Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barré Syndrome and Narcolepsy". CNS Drugs. 34 (1): 1–8. doi:10.1007/s40263-019-00670-y. PMC 7224038. PMID 31576507.
Ascherio A, Munger KL (June 2007). "Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors". Annals of Neurology. 61 (6): 504–13. doi:10.1002/ana.21141. PMID 17492755. S2CID 36999504.
Spitsin S, Koprowski H (2008). "Role of Uric Acid in Multiple Sclerosis". In Rodriguez M (ed.). Advances in multiple Sclerosis and Experimental Demyelinating Diseases. Current Topics in Microbiology and Immunology. Vol. 318. pp. 325–342. doi:10.1007/978-3-540-73677-6_13. ISBN 978-3-540-73676-9. PMID 18219824.
Nourbakhsh B, Mowry EM (June 2019). "Multiple Sclerosis Risk Factors and Pathogenesis". Continuum. 25 (3): 596–610. doi:10.1212/CON.0000000000000725. PMID 31162307. S2CID 174806511.
Miclea A, Bagnoud M, Chan A, Hoepner R (6 May 2020). "A Brief Review of the Effects of Vitamin D on Multiple Sclerosis". Frontiers in Immunology. 11 781. doi:10.3389/fimmu.2020.00781. ISSN 1664-3224. PMC 7218089. PMID 32435244.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. (February 2018). "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria". The Lancet. Neurology. 17 (2): 162–173. doi:10.1016/s1474-4422(17)30470-2. PMID 29275977. Archived from the original on 28 May 2023. Retrieved 20 January 2024.
Hassani A, Reguraman N, Shehab S, Khan G (2021). "Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis". Frontiers in Immunology. 12 764937. doi:10.3389/fimmu.2021.764937. PMC 8656284. PMID 34899715.
Chari DM (2007). "Remyelination in Multiple Sclerosis". In Minagar A (ed.). The Neurobiology of Multiple Sclerosis. International Review of Neurobiology. Vol. 79. pp. 589–620. doi:10.1016/S0074-7742(07)79026-8. ISBN 978-0-12-373736-6. PMC 7112255. PMID 17531860.
Pittock SJ, Lucchinetti CF (March 2007). "The pathology of MS: new insights and potential clinical applications". The Neurologist. 13 (2): 45–56. doi:10.1097/01.nrl.0000253065.31662.37. PMID 17351524. S2CID 2993523.
Huang X, Hussain B, Chang J (January 2021). "Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms". CNS Neuroscience & Therapeutics. 27 (1): 36–47. doi:10.1111/cns.13569. PMC 7804893. PMID 33381913.
Ferré JC, Shiroishi MS, Law M (November 2012). "Advanced techniques using contrast media in neuroimaging". Magnetic Resonance Imaging Clinics of North America. 20 (4): 699–713. doi:10.1016/j.mric.2012.07.007. PMC 3479680. PMID 23088946.
Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. (June 2019). "Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 90 (6): 642–651. doi:10.1136/jnnp-2018-320050. PMC 6581095. PMID 30683707.
Ellison PM, Goodall S, Kennedy N, Dawes H, Clark A, Pomeroy V, et al. (September 2022). "Neurostructural and Neurophysiological Correlates of Multiple Sclerosis Physical Fatigue: Systematic Review and Meta-Analysis of Cross-Sectional Studies". Neuropsychology Review. 32 (3): 506–519. doi:10.1007/s11065-021-09508-1. PMC 9381450. PMID 33961198.
Newland P, Starkweather A, Sorenson M (2016). "Central fatigue in multiple sclerosis: A review of the literature". The Journal of Spinal Cord Medicine. 39 (4): 386–399. doi:10.1080/10790268.2016.1168587. PMC 5102292. PMID 27146427.
Davis SL, Jay O, Wilson TE (2018). "Thermoregulatory dysfunction in multiple sclerosis". In Romanovsky AA (ed.). Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part II. Handbook of Clinical Neurology. Vol. 157. pp. 701–714. doi:10.1016/B978-0-444-64074-1.00042-2. ISBN 978-0-444-64074-1. PMID 30459034.
Loy BD, Taylor RL, Fling BW, Horak FB (September 2017). "Relationship between perceived fatigue and performance fatigability in people with multiple sclerosis: A systematic review and meta-analysis". Journal of Psychosomatic Research. 100: 1–7. doi:10.1016/j.jpsychores.2017.06.017. PMC 5875709. PMID 28789787.
Trojano M, Paolicelli D (November 2001). "The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes". Neurological Sciences. 22 (Suppl 2): S98-102. doi:10.1007/s100720100044. PMID 11794488. S2CID 3057096.
Poser CM, Brinar VV (June 2004). "Diagnostic criteria for multiple sclerosis: an historical review". Clinical Neurology and Neurosurgery. 106 (3): 147–58. doi:10.1016/j.clineuro.2004.02.004. PMID 15177763. S2CID 23452341.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. (July 2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis". Annals of Neurology. 50 (1): 121–7. doi:10.1002/ana.1032. PMID 11456302. S2CID 13870943.
Rashid W, Miller DH (February 2008). "Recent advances in neuroimaging of multiple sclerosis". Seminars in Neurology. 28 (1): 46–55. doi:10.1055/s-2007-1019127. PMID 18256986. S2CID 260317568.
Sinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, et al. (MAGNIMS Study Group) (December 2019). "Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis". JAMA Neurology. 76 (12): 1446–1456. doi:10.1001/jamaneurol.2019.2478. PMC 6704746. PMID 31424490.
Castellaro M, Tamanti A, Pisani AI, Pizzini FB, Crescenzo F, Calabrese M (November 2020). "The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis". Diagnostics. 10 (12): 1025. doi:10.3390/diagnostics10121025. PMC 7760678. PMID 33260401.
Guisset F, Lolli V, Bugli C, Perrotta G, Absil J, Dachy B, et al. (June 2021). "The central vein sign in multiple sclerosis patients with vascular comorbidities". Multiple Sclerosis. 27 (7): 1057–1065. doi:10.1177/1352458520943785. hdl:2078.1/239849. PMID 32749948.
Weigel M, Dechent P, Galbusera R, Bahn E, Nair G, Lu PJ, et al. (July 2021). "Imaging multiple sclerosis pathology at 160 μm isotropic resolution by human whole-brain ex vivo magnetic resonance imaging at 3 T". Scientific Reports. 11 (1) 15491. doi:10.1038/s41598-021-94891-1. PMC 8322069. PMID 34326420.
Link H, Huang YM (November 2006). "Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness". Journal of Neuroimmunology. 180 (1–2): 17–28. doi:10.1016/j.jneuroim.2006.07.006. PMID 16945427. S2CID 22724352.
Saguil A, Farnell IV EA, Jordan TS (August 2022). "Multiple Sclerosis: A Primary Care Perspective". American Family Physician. 106 (2): 173–183. PMID 35977131.
Solomon AJ (June 2019). "Diagnosis, Differential Diagnosis, and Misdiagnosis of Multiple Sclerosis". Continuum. 25 (3): 611–635. doi:10.1212/CON.0000000000000728. PMID 31162308. S2CID 173991777.
Lublin FD, et al. (15 July 2014). "Defining the clinical course of multiple sclerosis, The 2013 revisions". Neurology. 83 (3): 278–286. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.
Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ (June 2020). "The 2013 clinical course descriptors for multiple sclerosis: A clarification". Neurology. 94 (24): 1088–1092. doi:10.1212/WNL.0000000000009636. PMC 7455332. PMID 32471886.
Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (May 2005). "Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis". The Lancet. Neurology. 4 (5): 281–8. doi:10.1016/S1474-4422(05)70071-5. PMID 15847841. S2CID 36401666.
Miller DH, Leary SM (October 2007). "Primary-progressive multiple sclerosis". The Lancet. Neurology. 6 (10): 903–12. doi:10.1016/S1474-4422(07)70243-0. hdl:1871/24666. PMID 17884680. S2CID 31389841.
Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M (April 2006). "Secondary progressive multiple sclerosis: current knowledge and future challenges". The Lancet. Neurology. 5 (4): 343–54. doi:10.1016/S1474-4422(06)70410-0. PMID 16545751. S2CID 39503553.
Sørensen PS, Centonze D, Giovannoni G, et al. (2020). "Expert opinion on the use of cladribine tablets in clinical practice". Ther Adv Neurol Disord (Review). 13 1756286420935019. doi:10.1177/1756286420935019. PMC 7318823. PMID 32636933.
Saida T (November 2004). "多発性硬化症: 再燃時の治療と再発予防" [Multiple sclerosis: treatment and prevention of relapses and progression in multiple sclerosis]. 臨床神経学 [Rinsho Shinkeigaku] (Review) (in Japanese). 44 (11): 796–8. PMID 15651294.
Pittock SJ, Rodriguez M (2008). "Benign Multiple Sclerosis: A Distinct Clinical Entity with Therapeutic Implications". In Rodriguez M (ed.). Advances in multiple Sclerosis and Experimental Demyelinating Diseases. Current Topics in Microbiology and Immunology. Vol. 318. pp. 1–17. doi:10.1007/978-3-540-73677-6_1. ISBN 978-3-540-73676-9. PMID 18219812.
Stadelmann C, Brück W (November 2004). "Lessons from the neuropathology of atypical forms of multiple sclerosis". Neurological Sciences. 25 (Suppl 4): S319 – S322. doi:10.1007/s10072-004-0333-1. PMID 15727225. S2CID 21212935.
Fujihara K (June 2019). "Neuromyelitis optica spectrum disorders: still evolving and broadening". Current Opinion in Neurology (Review). 32 (3): 385–394. doi:10.1097/WCO.0000000000000694. PMC 6522202. PMID 30893099.
McGinley MP, Goldschmidt CH, Rae-Grant AD (February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765–779. doi:10.1001/jama.2020.26858. PMID 33620411. S2CID 232019589.
Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BA, Gronseth GS, et al. (April 2018). "Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology". Neurology. 90 (17): 777–788. doi:10.1212/WNL.0000000000005347. PMID 29686116.
Burton JM, O'Connor PW, Hohol M, Beyene J (December 2012). "Oral versus intravenous steroids for treatment of relapses in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2012 (12) CD006921. doi:10.1002/14651858.CD006921.pub3. PMC 12145957. PMID 23235634.
Filippini G, Brusaferri F, Sibley WA, et al. (2000). "Corticosteroids or ACTH for acute exacerbations in multiple sclerosis". Cochrane Database Syst Rev. 2013 (4) CD001331. doi:10.1002/14651858.CD001331. PMC 11391333. PMID 11034713.
The National Collaborating Centre for Chronic Conditions (2004). "Treatment of acute episodes". Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians. pp. 54–58. ISBN 1-86016-182-0. PMID 21290636. Archived from the original on 10 February 2023. Retrieved 5 October 2021.
Petzold A, Braithwaite T, van Oosten BW (January 2020). "Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence". J. Neurol. Neurosurg. Psychiatry (Review). 91 (1): 9–14. doi:10.1136/jnnp-2019-321653. PMC 6952848. PMID 31740484.
He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, et al. (March 2016). "Teriflunomide for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2016 (3) CD009882. doi:10.1002/14651858.CD009882.pub3. PMC 10493042. PMID 27003123.
Rice GP, Incorvaia B, Munari L, et al. (2001). "Interferon in relapsing-remitting multiple sclerosis". Cochrane Database Syst Rev. 2001 (4) CD002002. doi:10.1002/14651858.CD002002. PMC 7017973. PMID 11687131.
Hassan-Smith G, Douglas MR (November 2011). "Management and prognosis of multiple sclerosis". British Journal of Hospital Medicine. 72 (11): M174-6. doi:10.12968/hmed.2011.72.Sup11.M174. PMID 22082979.
Freedman MS (January 2011). "Long-term follow-up of clinical trials of multiple sclerosis therapies". Neurology. 76 (1 Suppl 1): S26-34. doi:10.1212/WNL.0b013e318205051d. PMID 21205679. S2CID 16929304.
Qizilbash N, Mendez I, Sanchez-de la Rosa R (January 2012). "Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis". Clinical Therapeutics. 34 (1): 159–176.e5. doi:10.1016/j.clinthera.2011.12.006. PMID 22284996.
Bates D (January 2011). "Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials". Neurology. 76 (1 Suppl 1): S14-25. doi:10.1212/WNL.0b013e3182050388. PMID 21205678. S2CID 362182.
Clerico M, Faggiano F, Palace J, et al. (April 2008). "Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis". Cochrane Database Syst Rev (2) CD005278. doi:10.1002/14651858.CD005278.pub3. PMID 18425915.
Johnston J, So TY (June 2012). "First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview". Drugs. 72 (9): 1195–211. doi:10.2165/11634010-000000000-00000. PMID 22642799. S2CID 20323687.
La Mantia L, Tramacere I, Firwana B, et al. (April 2016). "Fingolimod for relapsing-remitting multiple sclerosis". Cochrane Database Syst Rev. 2016 (4) CD009371. doi:10.1002/14651858.CD009371.pub2. PMC 10401910. PMID 27091121.
Xu Z, Zhang F, Sun F, et al. (April 2015). "Dimethyl fumarate for multiple sclerosis". Cochrane Database Syst Rev. 2015 (4) CD011076. doi:10.1002/14651858.CD011076.pub2. PMC 10663978. PMID 25900414.
Killestein J, Rudick RA, Polman CH (November 2011). "Oral treatment for multiple sclerosis". The Lancet. Neurology. 10 (11): 1026–34. doi:10.1016/S1474-4422(11)70228-9. PMID 22014437. S2CID 206160178.
Filippini G, Del Giovane C, Clerico M, et al. (April 2017). "Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis". Cochrane Database Syst Rev. 2017 (4) CD012200. doi:10.1002/14651858.CD012200.pub2. PMC 6478290. PMID 28440858.
Filippini G, Del Giovane C, Vacchi L, et al. (June 2013). "Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis". Cochrane Database Syst Rev (6) CD008933. doi:10.1002/14651858.CD008933.pub2. PMC 11627144. PMID 23744561.
La Mantia L, Di Pietrantonj C, Rovaris M, et al. (November 2016). "Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis". Cochrane Database Syst Rev. 2016 (11) CD009333. doi:10.1002/14651858.CD009333.pub3. PMC 6464642. PMID 27880972.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, Del Giovane C, Peryer G, Piggott T, et al. (January 2024). "Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis". Cochrane Database Syst Rev. 2024 (1) CD011381. doi:10.1002/14651858.CD011381.pub3. PMC 10765473. PMID 38174776.
Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G (May 2013). "Mitoxantrone for multiple sclerosis". The Cochrane Database of Systematic Reviews. 5 (5) CD002127. doi:10.1002/14651858.CD002127.pub3. hdl:2434/533488. PMC 11745300. PMID 23728638.
Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW (May 2010). "Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (18): 1463–70. doi:10.1212/WNL.0b013e3181dc1ae0. PMC 2871006. PMID 20439849.
Faissner S, Gold R (2019). "Progressive multiple sclerosis: latest therapeutic developments and future directions". Therapeutic Advances in Neurological Disorders. 12 1756286419878323. doi:10.1177/1756286419878323. PMC 6764045. PMID 31598138.
Lin M, Zhang J, Zhang Y, Luo J, Shi S, et al. (Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group) (May 2022). "Ocrelizumab for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2022 (5) CD013247. doi:10.1002/14651858.CD013247.pub2. PMC 9115862. PMID 35583174.
Balak DM, Hengstman GJ, Çakmak A, Thio HB (December 2012). "Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review". Multiple Sclerosis. 18 (12): 1705–17. doi:10.1177/1352458512438239. hdl:1765/73097. PMID 22371220.
Sládková T, Kostolanský F (2006). "The role of cytokines in the immune response to influenza A virus infection". Acta Virologica. 50 (3): 151–62. PMID 17131933.
La Mantia L, Munari LM, Lovati R (May 2010). "Glatiramer acetate for multiple sclerosis". The Cochrane Database of Systematic Reviews (5) CD004678. doi:10.1002/14651858.CD004678.pub2. PMID 20464733.
Tremlett H, Oger J (November 2004). "Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis". Journal of Neurology. 251 (11): 1297–303. doi:10.1007/s00415-004-0619-5. PMID 15592724. S2CID 12529733.
Comi G (October 2009). "Treatment of multiple sclerosis: role of natalizumab". Neurological Sciences. 30. 30 (S2): S155-8. doi:10.1007/s10072-009-0147-2. PMID 19882365. S2CID 25910077.
Hunt D, Giovannoni G (February 2012). "Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring". Practical Neurology. 12 (1): 25–35. doi:10.1136/practneurol-2011-000092. PMID 22258169. S2CID 46326042.
Kesselring J, Beer S (October 2005). "Symptomatic therapy and neurorehabilitation in multiple sclerosis". The Lancet. Neurology. 4 (10): 643–52. doi:10.1016/S1474-4422(05)70193-9. PMID 16168933. S2CID 28253186.
Khan F, Turner-Stokes L, Ng L, Kilpatrick T (April 2007). Khan F (ed.). "Multidisciplinary rehabilitation for adults with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2011 (2) CD006036. doi:10.1002/14651858.CD006036.pub2. PMC 8992048. PMID 17443610.
Köpke S, Solari A, Rahn A, Khan F, Heesen C, Giordano A (October 2018). "Information provision for people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2018 (10) CD008757. doi:10.1002/14651858.CD008757.pub3. PMC 6517040. PMID 30317542.
Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH (May 2005). "Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews". Clinical Rehabilitation. 19 (3): 247–54. doi:10.1191/0269215505cr870oa. hdl:1871/26505. PMID 15859525.
Steultjens EM, Dekker J, Bouter LM, Cardol M, Van de Nes JC, Van den Ende CH (2003). Steultjens EE (ed.). "Occupational therapy for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2010 (3) CD003608. doi:10.1002/14651858.CD003608. PMC 9022193. PMID 12917976.
Amatya B, Khan F, Galea M (January 2019). "Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews". The Cochrane Database of Systematic Reviews. 1 (1) CD012732. doi:10.1002/14651858.CD012732.pub2. PMC 6353175. PMID 30637728.
Heine M, van de Port I, Rietberg MB, van Wegen EE, Kwakkel G (September 2015). "Exercise therapy for fatigue in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2015 (9) CD009956. doi:10.1002/14651858.CD009956.pub2. PMC 9554249. PMID 26358158.
Gallien P, Nicolas B, Robineau S, Pétrilli S, Houedakor J, Durufle A (July 2007). "Physical training and multiple sclerosis". Annales de Réadaptation et de Médecine Physique. 50 (6): 373–6, 369–72. doi:10.1016/j.annrmp.2007.04.004. PMID 17482708.
Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G (January 2005). Kwakkel G (ed.). "Exercise therapy for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2005 (1) CD003980. doi:10.1002/14651858.CD003980.pub2. PMC 6485797. PMID 15674920.
Thomas PW, Thomas S, Hillier C, Galvin K, Baker R (January 2006). Thomas PW (ed.). "Psychological interventions for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2010 (1) CD004431. doi:10.1002/14651858.CD004431.pub2. PMC 8406851. PMID 16437487.
Rosti-Otajärvi EM, Hämäläinen PI (February 2014). "Neuropsychological rehabilitation for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2014 (2) CD009131. doi:10.1002/14651858.CD009131.pub3. PMC 10966661. PMID 24515630.
Latorraca CO, Martimbianco AL, Pachito DV, Torloni MR, Pacheco RL, Pereira JG, et al. (October 2019). "Palliative care interventions for people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2019 (10) CD012936. doi:10.1002/14651858.CD012936.pub2. PMC 6803560. PMID 31637711.
Hayes S, Galvin R, Kennedy C, Finlayson M, McGuigan C, Walsh CD, et al. (November 2019). "Interventions for preventing falls in people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2019 (11) CD012475. doi:10.1002/14651858.CD012475.pub2. PMC 6953359. PMID 31778221.
van den Akker LE, Beckerman H, Collette EH, Eijssen IC, Dekker J, de Groot V (November 2016). "Effectiveness of cognitive behavioral therapy for the treatment of fatigue in patients with multiple sclerosis: A systematic review and meta-analysis". Journal of Psychosomatic Research. 90: 33–42. doi:10.1016/j.jpsychores.2016.09.002. PMID 27772557.
Amatya B, Young J, Khan F (December 2018). "Non-pharmacological interventions for chronic pain in multiple sclerosis". The Cochrane Database of Systematic Reviews. 12 (12) CD012622. doi:10.1002/14651858.CD012622.pub2. PMC 6516893. PMID 30567012.
Corvillo I, Varela E, Armijo F, Alvarez-Badillo A, Armijo O, Maraver F (December 2017). "Efficacy of aquatic therapy for multiple sclerosis: a systematic review". Eur J Phys Rehabil Med (Review). 53 (6): 944–952. doi:10.23736/S1973-9087.17.04570-1. PMID 28215060.
Khan F, Amatya B, Bensmail D, Yelnik A (July 2019). "Non-pharmacological interventions for spasticity in adults: An overview of systematic reviews". Ann Phys Rehabil Med. 62 (4): 265–273. doi:10.1016/j.rehab.2017.10.001. PMID 29042299. S2CID 207497395.
Etoom M, Khraiwesh Y, Lena F, et al. (November 2018). "Effectiveness of Physiotherapy Interventions on Spasticity in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis". Am J Phys Med Rehabil. 97 (11): 793–807. doi:10.1097/PHM.0000000000000970. PMID 29794531. S2CID 44156766.
Huntley A (January 2006). "A review of the evidence for efficacy of complementary and alternative medicines in MS". International MS Journal. 13 (1): 5–12, 4. PMID 16420779.
Olsen SA (2009). "A review of complementary and alternative medicine (CAM) by people with multiple sclerosis". Occupational Therapy International. 16 (1): 57–70. doi:10.1002/oti.266. PMID 19222053.
Parks NE, Jackson-Tarlton CS, Vacchi L, Merdad R, Johnston BC (May 2020). "Dietary interventions for multiple sclerosis-related outcomes". The Cochrane Database of Systematic Reviews. 2020 (5) CD004192. doi:10.1002/14651858.CD004192.pub4. PMC 7388136. PMID 32428983.
Grigorian A, Araujo L, Naidu NN, Place DJ, Choudhury B, Demetriou M (November 2011). "N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis". The Journal of Biological Chemistry. 286 (46): 40133–41. doi:10.1074/jbc.M111.277814. PMC 3220534. PMID 21965673.
Pozuelo-Moyano B, Benito-León J, Mitchell AJ, Hernández-Gallego J (2013). "A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis". Neuroepidemiology (Systematic review). 40 (3): 147–53. doi:10.1159/000345122. PMC 3649517. PMID 23257784. the available evidence substantiates neither clinically significant benefit nor harm from vitamin D in the treatment of patients with MS
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E (October 2006). "Cannabis use in patients with multiple sclerosis". Multiple Sclerosis. 12 (5): 646–51. doi:10.1177/1352458506070947. PMID 17086912. S2CID 34692470.
Torres-Moreno MC, Papaseit E, Torrens M, Farré M (October 2018). "Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis". JAMA Network Open. 1 (6): e183485. doi:10.1001/jamanetworkopen.2018.3485. PMC 6324456. PMID 30646241.
Bennett M, Heard R (2004). Bennett MH (ed.). "Hyperbaric oxygen therapy for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2011 (1) CD003057. doi:10.1002/14651858.CD003057.pub2. PMC 8407327. PMID 14974004.
Simpson R, Booth J, Lawrence M, Byrne S, Mair F, Mercer S (January 2014). "Mindfulness based interventions in multiple sclerosis—a systematic review". BMC Neurology. 14 15. doi:10.1186/1471-2377-14-15. PMC 3900731. PMID 24438384.
Jagannath VA, Filippini G, Di Pietrantonj C, Asokan GV, Robak EW, Whamond L, et al. (September 2018). "Vitamin D for the management of multiple sclerosis". The Cochrane Database of Systematic Reviews. 9 (9) CD008422. doi:10.1002/14651858.CD008422.pub3. PMC 6513642. PMID 30246874.
Motte J, Gold R (December 2020). "High-dose biotin in multiple sclerosis: the end of the road". Lancet Neurol. 19 (12): 965–966. doi:10.1016/S1474-4422(20)30353-7. PMID 33222766. S2CID 225049079.
Tryfonos C, Mantzorou M, Fotiou D, Vrizas M, Vadikolias K, Pavlidou E, et al. (September 2019). "Dietary Supplements on Controlling Multiple Sclerosis Symptoms and Relapses: Current Clinical Evidence and Future Perspectives". Medicines. 6 (3): 95. doi:10.3390/medicines6030095. PMC 6789617. PMID 31547410.
Sedel F, Bernard D, Mock DM, Tourbah A (November 2016). "Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis". Neuropharmacology. 110 (Pt B): 644–653. doi:10.1016/j.neuropharm.2015.08.028. PMID 26327679.
Goldschmidt CH, Cohen JA (July 2020). "The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis". Neurotherapeutics. 17 (3): 968–970. doi:10.1007/s13311-020-00907-5. PMC 7609671. PMID 32761325.
Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K (May 2022). "Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 5 (5) CD013444. doi:10.1002/14651858.CD013444.pub2. PMC 9069991. PMID 35510826.
Cree BA, Hartung HP, Barnett M (June 2022). "New drugs for multiple sclerosis: new treatment algorithms". Curr Opin Neurol. 35 (3): 262–270. doi:10.1097/WCO.0000000000001063. PMID 35674067. S2CID 249438715.
Oh J, Vidal-Jordana A, Montalban X (December 2018). "Multiple sclerosis: clinical aspects". Curr Opin Neurol. 31 (6): 752–759. doi:10.1097/WCO.0000000000000622. PMID 30300239. Archived from the original on 25 November 2024. Retrieved 2 June 2024.
Hauser SL, Cree BA (December 2020). "Treatment of Multiple Sclerosis: A Review". Am J Med. 133 (12): 1380–1390.e2. doi:10.1016/j.amjmed.2020.05.049. PMC 7704606. PMID 32682869.
Ontaneda D (June 2019). "Progressive Multiple Sclerosis". Continuum. 25 (3): 736–752. doi:10.1212/CON.0000000000000727. PMID 31162314. S2CID 174808956.
Inojosa H, Proschmann U, Akgün K, Ziemssen T (April 2021). "A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition". J Neurol. 268 (4): 1210–1221. doi:10.1007/s00415-019-09489-5. PMID 31363847. S2CID 198999832. Expanded Disability Status Scale (EDSS) 6.0 is equivalent to requiring a walking aid, and EDSS 8.0 equivalent to chair or bedbound
Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (April 2018). "Multiple sclerosis". Lancet. 391 (10130): 1622–1636. doi:10.1016/S0140-6736(18)30481-1. PMID 29576504. S2CID 4313310.
Lunde HM, Assmus J, Myhr KM, Bø L, Grytten N (August 2017). "Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (8): 621–625. doi:10.1136/jnnp-2016-315238. PMC 5537547. PMID 28365589.
Kurtzke JF (October 1993). "Epidemiologic evidence for multiple sclerosis as an infection". Clinical Microbiology Reviews. 6 (4): 382–427. doi:10.1128/CMR.6.4.382. PMC 358295. PMID 8269393.
Alonso A, Hernán MA (July 2008). "Temporal trends in the incidence of multiple sclerosis: a systematic review". Neurology. 71 (2): 129–135. doi:10.1212/01.wnl.0000316802.35974.34. PMC 4109189. PMID 18606967.
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. (December 2020). "Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition". Multiple Sclerosis. 26 (14): 1816–1821. doi:10.1177/1352458520970841. PMC 7720355. PMID 33174475.
Compston A (October 1988). "The 150th anniversary of the first depiction of the lesions of multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 51 (10): 1249–52. doi:10.1136/jnnp.51.10.1249. PMC 1032909. PMID 3066846.
Lassmann H (October 1999). "The pathology of multiple sclerosis and its evolution". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354 (1390): 1635–40. doi:10.1098/rstb.1999.0508. PMC 1692680. PMID 10603616.
Lassmann H (July 2005). "Multiple sclerosis pathology: evolution of pathogenetic concepts". Brain Pathology. 15 (3): 217–22. doi:10.1111/j.1750-3639.2005.tb00523.x. PMC 8095927. PMID 16196388. S2CID 8342303.
Milo R, Miller A (April 2014). "Revised diagnostic criteria of multiple sclerosis". Autoimmunity Reviews. 13 (4–5): 518–524. doi:10.1016/j.autrev.2014.01.012. PMID 24424194.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. (February 2011). "Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria". Annals of Neurology. 69 (2): 292–302. doi:10.1002/ana.22366. PMC 3084507. PMID 21387374.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. (July 2014). "Defining the clinical course of multiple sclerosis: the 2013 revisions". Neurology. 83 (3): 278–86. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.
Sørensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, et al. (24 June 2020). "Expert opinion on the use of cladribine tablets in clinical practice". Therapeutic Advances in Neurological Disorders. 13 1756286420935019. doi:10.1177/1756286420935019. PMC 7318823. PMID 32636933.
Medaer R (September 1979). "Does the history of multiple sclerosis go back as far as the 14th century?". Acta Neurologica Scandinavica. 60 (3): 189–92. doi:10.1111/j.1600-0447.1979.tb08970.x. PMID 390966. S2CID 221422840.
Holmøy T (2006). "A Norse contribution to the history of neurological diseases". European Neurology. 55 (1): 57–8. doi:10.1159/000091431. PMID 16479124.
Pearce JM (2005). "Historical descriptions of multiple sclerosis". European Neurology. 54 (1): 49–53. doi:10.1159/000087387. PMID 16103678.
Petzold A (2013). "Optic Neuritis: Another Dickensian Diagnosis". Neuro-Ophthalmology. 37 (6): 247–250. doi:10.3109/01658107.2013.830313. PMC 5291069. PMID 28167994.
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, et al. (March 2020). "Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies". Trends in Molecular Medicine. 26 (3): 296–310. doi:10.1016/j.molmed.2019.11.003. PMC 7106557. PMID 31862243.
DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A (June 2006). "Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up". Archives of Neurology. 63 (6): 839–844. doi:10.1001/archneur.63.6.noc50328. PMID 16606758.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. (January 2017). "Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis". The New England Journal of Medicine. 376 (3): 221–234. doi:10.1056/NEJMoa1601277. hdl:2445/178507. PMID 28002679. S2CID 205099904.
Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. (March 2022). "Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM". Nature. 603 (7900): 321–327. Bibcode:2022Natur.603..321L. doi:10.1038/s41586-022-04432-7. PMC 9382663. PMID 35073561.
Morandi E, Tanasescu R, Tarlinton RE, Constantinescu CS, Zhang W, Tench C, et al. (16 February 2017). Ruprecht K (ed.). "The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis". PLOS ONE. 12 (2) e0172415. Bibcode:2017PLoSO..1272415M. doi:10.1371/journal.pone.0172415. PMC 5313176. PMID 28207850.
Rangel SC, da Silva MD, da Silva AL, Dos Santos JM, Neves LM, Pedrosa A, et al. (23 November 2022). "Human endogenous retroviruses and the inflammatory response: A vicious circle associated with health and illness". Frontiers in Immunology. 13 1057791. doi:10.3389/fimmu.2022.1057791. PMC 9744114. PMID 36518758.
Yang C, Hao Z, Zhang L, Zeng L, Wen J (October 2015). "Sodium channel blockers for neuroprotection in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2015 (10) CD010422. doi:10.1002/14651858.CD010422.pub2. PMC 9242538. PMID 26486929.
Kira JI, Yamasaki R, Ogata H (2019). "Anti-neurofascin autoantibody and demyelination". Neurochemistry International. 130 104360. doi:10.1016/j.neuint.2018.12.011. PMID 30582947.
Popescu BF, Pirko I, Lucchinetti CF (August 2013). "Pathology of multiple sclerosis: where do we stand?". Continuum. 19 (4 Multiple Sclerosis): 901–21. doi:10.1212/01.CON.0000433291.23091.65. PMC 3915566. PMID 23917093.
Mehta V, Pei W, Yang G, Li S, Swamy E, Boster A, et al. (2013). "Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions". PLOS ONE. 8 (3) e57573. Bibcode:2013PLoSO...857573M. doi:10.1371/journal.pone.0057573. PMC 3597727. PMID 23516409.
Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. (October 2018). "Neurofilaments as biomarkers in neurological disorders". Nature Reviews. Neurology. 14 (10): 577–589. doi:10.1038/s41582-018-0058-z. PMID 30171200.
Petzold A (June 2005). "Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss". Journal of the Neurological Sciences. 233 (1–2): 183–98. doi:10.1016/j.jns.2005.03.015. PMID 15896809.
Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, et al. (December 2011). "Magnetic resonance techniques in multiple sclerosis: the present and the future". Archives of Neurology. 68 (12): 1514–20. doi:10.1001/archneurol.2011.914. hdl:11365/20521. PMID 22159052.
Swanberg KM, Landheer K, Pitt D, Juchem C (2019). "Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker". Frontiers in Neurology. 10 1173. doi:10.3389/fneur.2019.01173. PMC 6876616. PMID 31803127.
Moghadasi AN, Mirmosayyeb O, Barzegar M, Sahraian MA, Ghajarzadeh M (August 2021). "The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis". Neurol Sci. 42 (8): 3093–3099. doi:10.1007/s10072-021-05373-1. PMC 8184129. PMID 34100130.
Neumann B, Baror R, Zhao C, Segel M, Dietmann S, Rawji KS, et al. (October 2019). "Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells". Cell Stem Cell. 25 (4): 473–485.e8. doi:10.1016/j.stem.2019.08.015. PMC 6863391. PMID 31585093.
Gilbert EA, Livingston J, Flores EG, Khan M, Kandavel H, Morshead CM (January 2024). "Metformin treatment reduces inflammation, dysmyelination and disease severity in a mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis". Brain Research. 1822 148648. doi:10.1016/j.brainres.2023.148648. PMID 37890574.
De Keersmaecker AV, Van Doninck E, Popescu V, Willem L, Cambron M, Laureys G, et al. (21 February 2024). "A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial". Frontiers in Immunology. 15 1362629. doi:10.3389/fimmu.2024.1362629. PMC 11046490. PMID 38680485.
Wasko NJ, Nichols F, Clark RB (January 2020). "Multiple sclerosis, the microbiome, TLR2, and the hygiene hypothesis". Autoimmunity Reviews. 19 (1) 102430. doi:10.1016/j.autrev.2019.102430. PMID 31734400.
Aranow C (August 2011). "Vitamin D and the immune system". Journal of Investigative Medicine. 59 (6): 881–886. doi:10.2310/jim.0b013e31821b8755. PMC 3166406. PMID 21527855.
Tada T, Takemori T, Okumura K, Nonaka M, Tokuhisa T (February 1978). "Two distinct types of helper T cells involved in the secondary antibody response: independent and synergistic effects of Ia- and Ia+ helper T cells". The Journal of Experimental Medicine. 147 (2): 446–458. doi:10.1084/jem.147.2.446. PMC 2184496. PMID 415110.
Lassmann H (March 2018). "Multiple Sclerosis Pathology". Cold Spring Harbor Perspectives in Medicine. 8 (3) a028936. doi:10.1101/cshperspect.a028936. PMC 5830904. PMID 29358320.
Allentoft ME, Sikora M, Refoyo-Martínez A, Irving-Pease EK, Fischer A, Barrie W, et al. (11 January 2024). "Population genomics of post-glacial western Eurasia". Nature. 625 (7994): 301–311. Bibcode:2024Natur.625..301A. doi:10.1038/s41586-023-06865-0. PMC 10781627. PMID 38200295.

ncbi.nlm.nih.gov

Mazumder R, Murchison C, Bourdette D, Cameron M (25 September 2014). "Falls in people with multiple sclerosis compared with falls in healthy controls". PLOS ONE. 9 (9) e107620. Bibcode:2014PLoSO...9j7620M. doi:10.1371/journal.pone.0107620. PMC 4177842. PMID 25254633.
Ford H (July 2020). "Clinical presentation and diagnosis of multiple sclerosis". Clinical Medicine. 20 (4). London, England: 380–383. doi:10.7861/clinmed.2020-0292. ISSN 1473-4893. PMC 7385797. PMID 32675142.
Loma I, Heyman R (September 2011). "Multiple sclerosis: pathogenesis and treatment". Current Neuropharmacology. 9 (3): 409–416. doi:10.2174/157015911796557911. PMC 3151595. PMID 22379455.
Wecker S, Freudenstein D, Ganser I, Angstwurm K, Lee DH, Linker RA (2024). "The impact of different lifestyle factors on disability in multiple sclerosis at older ages: a monocentric retrospective study". Therapeutic Advances in Neurological Disorders. 17 17562864241284166. doi:10.1177/17562864241284166. ISSN 1756-2856. PMC 11528639. PMID 39494114.
Bakalidou D, Giannopapas V, Giannopoulos S (July 2023). "Thoughts on Fatigue in Multiple Sclerosis Patients". Cureus. 15 (7) e42146. doi:10.7759/cureus.42146. PMC 10438195. PMID 37602098.
Plotas P, Nanousi V, Kantanis A, Tsiamaki E, Papadopoulos A, Tsapara A, et al. (July 2023). "Speech deficits in multiple sclerosis: a narrative review of the existing literature". European Journal of Medical Research. 28 (1) 252. doi:10.1186/s40001-023-01230-3. PMC 10364432. PMID 37488623.
Ghasemi N, Razavi S, Nikzad E (January 2017). "Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy". Cell Journal. 19 (1): 1–10. doi:10.22074/cellj.2016.4867 (inactive 1 July 2025). PMC 5241505. PMID 28367411.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez MÁ, Meca-Lallana V, Ramió-Torrentà L (2019). "Cognitive Dysfunctions and Assessments in Multiple Sclerosis". Frontiers in Neurology. 10 581. doi:10.3389/fneur.2019.00581. PMC 6558141. PMID 31214113.
Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. (November 2018). "Recommendations for cognitive screening and management in multiple sclerosis care". Multiple Sclerosis. 24 (13): 1665–1680. doi:10.1177/1352458518803785. PMC 6238181. PMID 30303036.
Benedict RH, Amato MP, DeLuca J, Geurts JJ (October 2020). "Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues". The Lancet. Neurology. 19 (10): 860–871. doi:10.1016/S1474-4422(20)30277-5. PMC 10011205. PMID 32949546. S2CID 221744328.
Christogianni A, Bibb R, Davis SL, Jay O, Barnett M, Evangelou N, et al. (17 January 2018). "Temperature sensitivity in multiple sclerosis: An overview of its impact on sensory and cognitive symptoms". Temperature. 5 (3): 208–223. doi:10.1080/23328940.2018.1475831. PMC 6205043. PMID 30377640.
van Munster CE, Uitdehaag BM (March 2017). "Outcome Measures in Clinical Trials for Multiple Sclerosis". CNS Drugs. 31 (3): 217–236. doi:10.1007/s40263-017-0412-5. PMC 5336539. PMID 28185158.
Makhani N, Tremlett H (August 2021). "The multiple sclerosis prodrome". Nature Reviews. Neurology. 17 (8): 515–521. doi:10.1038/s41582-021-00519-3. PMC 8324569. PMID 34155379.
Grimaldi L, Papeix C, Hamon Y, Buchard A, Moride Y, Benichou J, et al. (October 2023). "Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups". JAMA Neurology. 80 (10): 1098–1104. doi:10.1001/jamaneurol.2023.2968. PMC 10481324. PMID 37669073.
Varytė G, Zakarevičienė J, Ramašauskaitė D, Laužikienė D, Arlauskienė A (January 2020). "Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity". Medicina. 56 (2): 49. doi:10.3390/medicina56020049. PMC 7074401. PMID 31973138.
Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. (November 2007). "Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain". The Journal of Experimental Medicine. 204 (12): 2899–2912. doi:10.1084/jem.20071030. PMC 2118531. PMID 17984305.
Hassani A, Corboy JR, Al-Salam S, Khan G (2018). "Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells". PLOS ONE. 13 (2) e0192109. Bibcode:2018PLoSO..1392109H. doi:10.1371/journal.pone.0192109. PMC 5796799. PMID 29394264.
Lutterotti A, Hayward-Koennecke H, Sospedra M, Martin R (2021). "Antigen-Specific Immune Tolerance in Multiple Sclerosis-Promising Approaches and How to Bring Them to Patients". Frontiers in Immunology. 12 640935. doi:10.3389/fimmu.2021.640935. PMC 8019937. PMID 33828551.
Gilden DH (March 2005). "Infectious causes of multiple sclerosis". The Lancet. Neurology. 4 (3): 195–202. doi:10.1016/S1474-4422(05)01017-3. PMC 7129502. PMID 15721830.
Soldan SS, Lieberman PM (January 2023). "Epstein-Barr virus and multiple sclerosis". Nature Reviews. Microbiology. 21 (1): 51–64. doi:10.1038/s41579-022-00770-5. PMC 9362539. PMID 35931816.
Münz C (May 2004). "Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target". The Journal of Experimental Medicine. 199 (10): 1301–1304. doi:10.1084/jem.20040730. PMC 2211815. PMID 15148332.
Miclea A, Bagnoud M, Chan A, Hoepner R (6 May 2020). "A Brief Review of the Effects of Vitamin D on Multiple Sclerosis". Frontiers in Immunology. 11 781. doi:10.3389/fimmu.2020.00781. PMC 7218089. PMID 32435244.
Skene NG, Grant SG (2016). "Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment". Frontiers in Neuroscience. 10: 16. doi:10.3389/fnins.2016.00016. PMC 4730103. PMID 26858593.
Baranzini SE (June 2011). "Revealing the genetic basis of multiple sclerosis: are we there yet?". Current Opinion in Genetics & Development. 21 (3): 317–24. doi:10.1016/j.gde.2010.12.006. PMC 3105160. PMID 21247752.
International Multiple Sclerosis Genetics Consortium (2019). "Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility". Science. 365 (6460) eaav7188. doi:10.1126/science.aav7188. PMC 7241648. PMID 31604244.
Sintzel MB, Rametta M, Reder AT (1 June 2018). "Vitamin D and Multiple Sclerosis: A Comprehensive Review". Neurology and Therapy. 7 (1): 59–85. doi:10.1007/s40120-017-0086-4. ISSN 2193-6536. PMC 5990512. PMID 29243029.
Vitturi BK, Montecucco A, Rahmani A, Dini G, Durando P (15 November 2023). "Occupational risk factors for multiple sclerosis: a systematic review with meta-analysis". Frontiers in Public Health. 11 (2023): Introduction, Results. Bibcode:2023FrPH...1185103V. doi:10.3389/fpubh.2023.1285103. PMC 10694508. PMID 38054069.
Stowe J, Andrews N, Miller E (January 2020). "Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barré Syndrome and Narcolepsy". CNS Drugs. 34 (1): 1–8. doi:10.1007/s40263-019-00670-y. PMC 7224038. PMID 31576507.
Miclea A, Bagnoud M, Chan A, Hoepner R (6 May 2020). "A Brief Review of the Effects of Vitamin D on Multiple Sclerosis". Frontiers in Immunology. 11 781. doi:10.3389/fimmu.2020.00781. ISSN 1664-3224. PMC 7218089. PMID 32435244.
Hassani A, Reguraman N, Shehab S, Khan G (2021). "Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis". Frontiers in Immunology. 12 764937. doi:10.3389/fimmu.2021.764937. PMC 8656284. PMID 34899715.
Chari DM (2007). "Remyelination in Multiple Sclerosis". In Minagar A (ed.). The Neurobiology of Multiple Sclerosis. International Review of Neurobiology. Vol. 79. pp. 589–620. doi:10.1016/S0074-7742(07)79026-8. ISBN 978-0-12-373736-6. PMC 7112255. PMID 17531860.
Huang X, Hussain B, Chang J (January 2021). "Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms". CNS Neuroscience & Therapeutics. 27 (1): 36–47. doi:10.1111/cns.13569. PMC 7804893. PMID 33381913.
Ferré JC, Shiroishi MS, Law M (November 2012). "Advanced techniques using contrast media in neuroimaging". Magnetic Resonance Imaging Clinics of North America. 20 (4): 699–713. doi:10.1016/j.mric.2012.07.007. PMC 3479680. PMID 23088946.
Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. (June 2019). "Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 90 (6): 642–651. doi:10.1136/jnnp-2018-320050. PMC 6581095. PMID 30683707.
Ellison PM, Goodall S, Kennedy N, Dawes H, Clark A, Pomeroy V, et al. (September 2022). "Neurostructural and Neurophysiological Correlates of Multiple Sclerosis Physical Fatigue: Systematic Review and Meta-Analysis of Cross-Sectional Studies". Neuropsychology Review. 32 (3): 506–519. doi:10.1007/s11065-021-09508-1. PMC 9381450. PMID 33961198.
Newland P, Starkweather A, Sorenson M (2016). "Central fatigue in multiple sclerosis: A review of the literature". The Journal of Spinal Cord Medicine. 39 (4): 386–399. doi:10.1080/10790268.2016.1168587. PMC 5102292. PMID 27146427.
Loy BD, Taylor RL, Fling BW, Horak FB (September 2017). "Relationship between perceived fatigue and performance fatigability in people with multiple sclerosis: A systematic review and meta-analysis". Journal of Psychosomatic Research. 100: 1–7. doi:10.1016/j.jpsychores.2017.06.017. PMC 5875709. PMID 28789787.
Sinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, et al. (MAGNIMS Study Group) (December 2019). "Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis". JAMA Neurology. 76 (12): 1446–1456. doi:10.1001/jamaneurol.2019.2478. PMC 6704746. PMID 31424490.
Castellaro M, Tamanti A, Pisani AI, Pizzini FB, Crescenzo F, Calabrese M (November 2020). "The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis". Diagnostics. 10 (12): 1025. doi:10.3390/diagnostics10121025. PMC 7760678. PMID 33260401.
Weigel M, Dechent P, Galbusera R, Bahn E, Nair G, Lu PJ, et al. (July 2021). "Imaging multiple sclerosis pathology at 160 μm isotropic resolution by human whole-brain ex vivo magnetic resonance imaging at 3 T". Scientific Reports. 11 (1) 15491. doi:10.1038/s41598-021-94891-1. PMC 8322069. PMID 34326420.
Lublin FD, et al. (15 July 2014). "Defining the clinical course of multiple sclerosis, The 2013 revisions". Neurology. 83 (3): 278–286. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.
Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ (June 2020). "The 2013 clinical course descriptors for multiple sclerosis: A clarification". Neurology. 94 (24): 1088–1092. doi:10.1212/WNL.0000000000009636. PMC 7455332. PMID 32471886.
Sørensen PS, Centonze D, Giovannoni G, et al. (2020). "Expert opinion on the use of cladribine tablets in clinical practice". Ther Adv Neurol Disord (Review). 13 1756286420935019. doi:10.1177/1756286420935019. PMC 7318823. PMID 32636933.
Fujihara K (June 2019). "Neuromyelitis optica spectrum disorders: still evolving and broadening". Current Opinion in Neurology (Review). 32 (3): 385–394. doi:10.1097/WCO.0000000000000694. PMC 6522202. PMID 30893099.
Burton JM, O'Connor PW, Hohol M, Beyene J (December 2012). "Oral versus intravenous steroids for treatment of relapses in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2012 (12) CD006921. doi:10.1002/14651858.CD006921.pub3. PMC 12145957. PMID 23235634.
Filippini G, Brusaferri F, Sibley WA, et al. (2000). "Corticosteroids or ACTH for acute exacerbations in multiple sclerosis". Cochrane Database Syst Rev. 2013 (4) CD001331. doi:10.1002/14651858.CD001331. PMC 11391333. PMID 11034713.
The National Collaborating Centre for Chronic Conditions (2004). "Treatment of acute episodes". Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians. pp. 54–58. ISBN 1-86016-182-0. PMID 21290636. Archived from the original on 10 February 2023. Retrieved 5 October 2021.
Petzold A, Braithwaite T, van Oosten BW (January 2020). "Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence". J. Neurol. Neurosurg. Psychiatry (Review). 91 (1): 9–14. doi:10.1136/jnnp-2019-321653. PMC 6952848. PMID 31740484.
He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, et al. (March 2016). "Teriflunomide for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2016 (3) CD009882. doi:10.1002/14651858.CD009882.pub3. PMC 10493042. PMID 27003123.
Rice GP, Incorvaia B, Munari L, et al. (2001). "Interferon in relapsing-remitting multiple sclerosis". Cochrane Database Syst Rev. 2001 (4) CD002002. doi:10.1002/14651858.CD002002. PMC 7017973. PMID 11687131.
La Mantia L, Tramacere I, Firwana B, et al. (April 2016). "Fingolimod for relapsing-remitting multiple sclerosis". Cochrane Database Syst Rev. 2016 (4) CD009371. doi:10.1002/14651858.CD009371.pub2. PMC 10401910. PMID 27091121.
Xu Z, Zhang F, Sun F, et al. (April 2015). "Dimethyl fumarate for multiple sclerosis". Cochrane Database Syst Rev. 2015 (4) CD011076. doi:10.1002/14651858.CD011076.pub2. PMC 10663978. PMID 25900414.
Filippini G, Del Giovane C, Clerico M, et al. (April 2017). "Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis". Cochrane Database Syst Rev. 2017 (4) CD012200. doi:10.1002/14651858.CD012200.pub2. PMC 6478290. PMID 28440858.
Filippini G, Del Giovane C, Vacchi L, et al. (June 2013). "Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis". Cochrane Database Syst Rev (6) CD008933. doi:10.1002/14651858.CD008933.pub2. PMC 11627144. PMID 23744561.
La Mantia L, Di Pietrantonj C, Rovaris M, et al. (November 2016). "Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis". Cochrane Database Syst Rev. 2016 (11) CD009333. doi:10.1002/14651858.CD009333.pub3. PMC 6464642. PMID 27880972.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, Del Giovane C, Peryer G, Piggott T, et al. (January 2024). "Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis". Cochrane Database Syst Rev. 2024 (1) CD011381. doi:10.1002/14651858.CD011381.pub3. PMC 10765473. PMID 38174776.
Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G (May 2013). "Mitoxantrone for multiple sclerosis". The Cochrane Database of Systematic Reviews. 5 (5) CD002127. doi:10.1002/14651858.CD002127.pub3. hdl:2434/533488. PMC 11745300. PMID 23728638.
Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW (May 2010). "Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (18): 1463–70. doi:10.1212/WNL.0b013e3181dc1ae0. PMC 2871006. PMID 20439849.
Faissner S, Gold R (2019). "Progressive multiple sclerosis: latest therapeutic developments and future directions". Therapeutic Advances in Neurological Disorders. 12 1756286419878323. doi:10.1177/1756286419878323. PMC 6764045. PMID 31598138.
Lin M, Zhang J, Zhang Y, Luo J, Shi S, et al. (Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group) (May 2022). "Ocrelizumab for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2022 (5) CD013247. doi:10.1002/14651858.CD013247.pub2. PMC 9115862. PMID 35583174.
Khan F, Turner-Stokes L, Ng L, Kilpatrick T (April 2007). Khan F (ed.). "Multidisciplinary rehabilitation for adults with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2011 (2) CD006036. doi:10.1002/14651858.CD006036.pub2. PMC 8992048. PMID 17443610.
Köpke S, Solari A, Rahn A, Khan F, Heesen C, Giordano A (October 2018). "Information provision for people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2018 (10) CD008757. doi:10.1002/14651858.CD008757.pub3. PMC 6517040. PMID 30317542.
Steultjens EM, Dekker J, Bouter LM, Cardol M, Van de Nes JC, Van den Ende CH (2003). Steultjens EE (ed.). "Occupational therapy for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2010 (3) CD003608. doi:10.1002/14651858.CD003608. PMC 9022193. PMID 12917976.
Amatya B, Khan F, Galea M (January 2019). "Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews". The Cochrane Database of Systematic Reviews. 1 (1) CD012732. doi:10.1002/14651858.CD012732.pub2. PMC 6353175. PMID 30637728.
Heine M, van de Port I, Rietberg MB, van Wegen EE, Kwakkel G (September 2015). "Exercise therapy for fatigue in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2015 (9) CD009956. doi:10.1002/14651858.CD009956.pub2. PMC 9554249. PMID 26358158.
Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G (January 2005). Kwakkel G (ed.). "Exercise therapy for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2005 (1) CD003980. doi:10.1002/14651858.CD003980.pub2. PMC 6485797. PMID 15674920.
Thomas PW, Thomas S, Hillier C, Galvin K, Baker R (January 2006). Thomas PW (ed.). "Psychological interventions for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2010 (1) CD004431. doi:10.1002/14651858.CD004431.pub2. PMC 8406851. PMID 16437487.
Rosti-Otajärvi EM, Hämäläinen PI (February 2014). "Neuropsychological rehabilitation for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2014 (2) CD009131. doi:10.1002/14651858.CD009131.pub3. PMC 10966661. PMID 24515630.
Latorraca CO, Martimbianco AL, Pachito DV, Torloni MR, Pacheco RL, Pereira JG, et al. (October 2019). "Palliative care interventions for people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2019 (10) CD012936. doi:10.1002/14651858.CD012936.pub2. PMC 6803560. PMID 31637711.
Hayes S, Galvin R, Kennedy C, Finlayson M, McGuigan C, Walsh CD, et al. (November 2019). "Interventions for preventing falls in people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 2019 (11) CD012475. doi:10.1002/14651858.CD012475.pub2. PMC 6953359. PMID 31778221.
Amatya B, Young J, Khan F (December 2018). "Non-pharmacological interventions for chronic pain in multiple sclerosis". The Cochrane Database of Systematic Reviews. 12 (12) CD012622. doi:10.1002/14651858.CD012622.pub2. PMC 6516893. PMID 30567012.
Parks NE, Jackson-Tarlton CS, Vacchi L, Merdad R, Johnston BC (May 2020). "Dietary interventions for multiple sclerosis-related outcomes". The Cochrane Database of Systematic Reviews. 2020 (5) CD004192. doi:10.1002/14651858.CD004192.pub4. PMC 7388136. PMID 32428983.
Grigorian A, Araujo L, Naidu NN, Place DJ, Choudhury B, Demetriou M (November 2011). "N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis". The Journal of Biological Chemistry. 286 (46): 40133–41. doi:10.1074/jbc.M111.277814. PMC 3220534. PMID 21965673.
Pozuelo-Moyano B, Benito-León J, Mitchell AJ, Hernández-Gallego J (2013). "A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis". Neuroepidemiology (Systematic review). 40 (3): 147–53. doi:10.1159/000345122. PMC 3649517. PMID 23257784. the available evidence substantiates neither clinically significant benefit nor harm from vitamin D in the treatment of patients with MS
Torres-Moreno MC, Papaseit E, Torrens M, Farré M (October 2018). "Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis". JAMA Network Open. 1 (6): e183485. doi:10.1001/jamanetworkopen.2018.3485. PMC 6324456. PMID 30646241.
Bennett M, Heard R (2004). Bennett MH (ed.). "Hyperbaric oxygen therapy for multiple sclerosis". The Cochrane Database of Systematic Reviews. 2011 (1) CD003057. doi:10.1002/14651858.CD003057.pub2. PMC 8407327. PMID 14974004.
Simpson R, Booth J, Lawrence M, Byrne S, Mair F, Mercer S (January 2014). "Mindfulness based interventions in multiple sclerosis—a systematic review". BMC Neurology. 14 15. doi:10.1186/1471-2377-14-15. PMC 3900731. PMID 24438384.
Jagannath VA, Filippini G, Di Pietrantonj C, Asokan GV, Robak EW, Whamond L, et al. (September 2018). "Vitamin D for the management of multiple sclerosis". The Cochrane Database of Systematic Reviews. 9 (9) CD008422. doi:10.1002/14651858.CD008422.pub3. PMC 6513642. PMID 30246874.
Tryfonos C, Mantzorou M, Fotiou D, Vrizas M, Vadikolias K, Pavlidou E, et al. (September 2019). "Dietary Supplements on Controlling Multiple Sclerosis Symptoms and Relapses: Current Clinical Evidence and Future Perspectives". Medicines. 6 (3): 95. doi:10.3390/medicines6030095. PMC 6789617. PMID 31547410.
Goldschmidt CH, Cohen JA (July 2020). "The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis". Neurotherapeutics. 17 (3): 968–970. doi:10.1007/s13311-020-00907-5. PMC 7609671. PMID 32761325.
Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K (May 2022). "Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis". The Cochrane Database of Systematic Reviews. 5 (5) CD013444. doi:10.1002/14651858.CD013444.pub2. PMC 9069991. PMID 35510826.
Hauser SL, Cree BA (December 2020). "Treatment of Multiple Sclerosis: A Review". Am J Med. 133 (12): 1380–1390.e2. doi:10.1016/j.amjmed.2020.05.049. PMC 7704606. PMID 32682869.
Lunde HM, Assmus J, Myhr KM, Bø L, Grytten N (August 2017). "Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (8): 621–625. doi:10.1136/jnnp-2016-315238. PMC 5537547. PMID 28365589.
Kurtzke JF (October 1993). "Epidemiologic evidence for multiple sclerosis as an infection". Clinical Microbiology Reviews. 6 (4): 382–427. doi:10.1128/CMR.6.4.382. PMC 358295. PMID 8269393.
Alonso A, Hernán MA (July 2008). "Temporal trends in the incidence of multiple sclerosis: a systematic review". Neurology. 71 (2): 129–135. doi:10.1212/01.wnl.0000316802.35974.34. PMC 4109189. PMID 18606967.
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. (December 2020). "Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition". Multiple Sclerosis. 26 (14): 1816–1821. doi:10.1177/1352458520970841. PMC 7720355. PMID 33174475.
Compston A (October 1988). "The 150th anniversary of the first depiction of the lesions of multiple sclerosis". Journal of Neurology, Neurosurgery, and Psychiatry. 51 (10): 1249–52. doi:10.1136/jnnp.51.10.1249. PMC 1032909. PMID 3066846.
Lassmann H (October 1999). "The pathology of multiple sclerosis and its evolution". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354 (1390): 1635–40. doi:10.1098/rstb.1999.0508. PMC 1692680. PMID 10603616.
Lassmann H (July 2005). "Multiple sclerosis pathology: evolution of pathogenetic concepts". Brain Pathology. 15 (3): 217–22. doi:10.1111/j.1750-3639.2005.tb00523.x. PMC 8095927. PMID 16196388. S2CID 8342303.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. (February 2011). "Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria". Annals of Neurology. 69 (2): 292–302. doi:10.1002/ana.22366. PMC 3084507. PMID 21387374.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. (July 2014). "Defining the clinical course of multiple sclerosis: the 2013 revisions". Neurology. 83 (3): 278–86. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.
Sørensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, et al. (24 June 2020). "Expert opinion on the use of cladribine tablets in clinical practice". Therapeutic Advances in Neurological Disorders. 13 1756286420935019. doi:10.1177/1756286420935019. PMC 7318823. PMID 32636933.
Petzold A (2013). "Optic Neuritis: Another Dickensian Diagnosis". Neuro-Ophthalmology. 37 (6): 247–250. doi:10.3109/01658107.2013.830313. PMC 5291069. PMID 28167994.
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, et al. (March 2020). "Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies". Trends in Molecular Medicine. 26 (3): 296–310. doi:10.1016/j.molmed.2019.11.003. PMC 7106557. PMID 31862243.
Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. (March 2022). "Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM". Nature. 603 (7900): 321–327. Bibcode:2022Natur.603..321L. doi:10.1038/s41586-022-04432-7. PMC 9382663. PMID 35073561.
Morandi E, Tanasescu R, Tarlinton RE, Constantinescu CS, Zhang W, Tench C, et al. (16 February 2017). Ruprecht K (ed.). "The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis". PLOS ONE. 12 (2) e0172415. Bibcode:2017PLoSO..1272415M. doi:10.1371/journal.pone.0172415. PMC 5313176. PMID 28207850.
Rangel SC, da Silva MD, da Silva AL, Dos Santos JM, Neves LM, Pedrosa A, et al. (23 November 2022). "Human endogenous retroviruses and the inflammatory response: A vicious circle associated with health and illness". Frontiers in Immunology. 13 1057791. doi:10.3389/fimmu.2022.1057791. PMC 9744114. PMID 36518758.
Yang C, Hao Z, Zhang L, Zeng L, Wen J (October 2015). "Sodium channel blockers for neuroprotection in multiple sclerosis". The Cochrane Database of Systematic Reviews. 2015 (10) CD010422. doi:10.1002/14651858.CD010422.pub2. PMC 9242538. PMID 26486929.
Popescu BF, Pirko I, Lucchinetti CF (August 2013). "Pathology of multiple sclerosis: where do we stand?". Continuum. 19 (4 Multiple Sclerosis): 901–21. doi:10.1212/01.CON.0000433291.23091.65. PMC 3915566. PMID 23917093.
Mehta V, Pei W, Yang G, Li S, Swamy E, Boster A, et al. (2013). "Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions". PLOS ONE. 8 (3) e57573. Bibcode:2013PLoSO...857573M. doi:10.1371/journal.pone.0057573. PMC 3597727. PMID 23516409.
Swanberg KM, Landheer K, Pitt D, Juchem C (2019). "Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker". Frontiers in Neurology. 10 1173. doi:10.3389/fneur.2019.01173. PMC 6876616. PMID 31803127.
Moghadasi AN, Mirmosayyeb O, Barzegar M, Sahraian MA, Ghajarzadeh M (August 2021). "The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis". Neurol Sci. 42 (8): 3093–3099. doi:10.1007/s10072-021-05373-1. PMC 8184129. PMID 34100130.
Neumann B, Baror R, Zhao C, Segel M, Dietmann S, Rawji KS, et al. (October 2019). "Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells". Cell Stem Cell. 25 (4): 473–485.e8. doi:10.1016/j.stem.2019.08.015. PMC 6863391. PMID 31585093.
De Keersmaecker AV, Van Doninck E, Popescu V, Willem L, Cambron M, Laureys G, et al. (21 February 2024). "A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial". Frontiers in Immunology. 15 1362629. doi:10.3389/fimmu.2024.1362629. PMC 11046490. PMID 38680485.
Aranow C (August 2011). "Vitamin D and the immune system". Journal of Investigative Medicine. 59 (6): 881–886. doi:10.2310/jim.0b013e31821b8755. PMC 3166406. PMID 21527855.
Tada T, Takemori T, Okumura K, Nonaka M, Tokuhisa T (February 1978). "Two distinct types of helper T cells involved in the secondary antibody response: independent and synergistic effects of Ia- and Ia+ helper T cells". The Journal of Experimental Medicine. 147 (2): 446–458. doi:10.1084/jem.147.2.446. PMC 2184496. PMID 415110.
Lassmann H (March 2018). "Multiple Sclerosis Pathology". Cold Spring Harbor Perspectives in Medicine. 8 (3) a028936. doi:10.1101/cshperspect.a028936. PMC 5830904. PMID 29358320.
Allentoft ME, Sikora M, Refoyo-Martínez A, Irving-Pease EK, Fischer A, Barrie W, et al. (11 January 2024). "Population genomics of post-glacial western Eurasia". Nature. 625 (7994): 301–311. Bibcode:2024Natur.625..301A. doi:10.1038/s41586-023-06865-0. PMC 10781627. PMID 38200295.

ninds.nih.gov

"NINDS Multiple Sclerosis Information Page". National Institute of Neurological Disorders and Stroke. 30 June 2025. Archived from the original on 4 June 2025. Retrieved 30 June 2025.

dailymed.nlm.nih.gov

"Ocrevus- ocrelizumab injection". DailyMed. 13 December 2019. Archived from the original on 27 June 2020. Retrieved 26 March 2020.

novartis.com (Global: low place; English: low place)

"Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease". Novartis.com. Archived from the original on 20 November 2020. Retrieved 12 November 2021.

practicalneurology.com (Global: low place; English: low place)

Bernitsas E (February 2020). "The Central Vein Sign". Practical Neurology. Archived from the original on 5 October 2021. Retrieved 5 October 2021.

prnewswire.com (Global: 406^th place; English: 258^th place)

"Halozyme Announces FDA Approval of Roche's Subcutaneous Ocrevus Zunovo with Enhanze for People with Relapsing and Primary Progressive Multiple Sclerosis" (Press release). Halozyme Therapeutics. 13 September 2024. Archived from the original on 14 September 2024. Retrieved 13 September 2024 – via PR Newswire.

psu.edu (Global: 207^th place; English: 136^th place)

citeseerx.ist.psu.edu

Dyment DA, Ebers GC, Sadovnick AD (February 2004). "Genetics of multiple sclerosis". The Lancet. Neurology. 3 (2): 104–10. CiteSeerX 10.1.1.334.1312. doi:10.1016/S1474-4422(03)00663-X. PMID 14747002. S2CID 16707321.

qub.ac.uk (Global: 8,565^th place; English: 5,337^th place)

"New treatment hope as world-first MS mega-trial opens site in Northern Ireland". www.qub.ac.uk. 6 June 2023. Archived from the original on 30 July 2024. Retrieved 30 July 2024.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Compston A, Coles A (October 2008). "Multiple sclerosis". Lancet. 372 (9648): 1502–1517. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977. S2CID 195686659.
Nakahara J, Maeda M, Aiso S, Suzuki N (February 2012). "Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy". Clinical Reviews in Allergy & Immunology. 42 (1): 26–34. doi:10.1007/s12016-011-8287-6. PMID 22189514. S2CID 21058811.
Liu Z, Liao Q, Wen H, Zhang Y (June 2021). "Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis". Autoimmunity Reviews. 20 (6) 102826. doi:10.1016/j.autrev.2021.102826. PMID 33878488. S2CID 233325057.
Alphonsus KB, Su Y, D'Arcy C (April 2019). "The effect of exercise, yoga and physiotherapy on the quality of life of people with multiple sclerosis: Systematic review and meta-analysis". Complementary Therapies in Medicine. 43: 188–195. doi:10.1016/j.ctim.2019.02.010. PMID 30935529. S2CID 86669723.
Compston A, Coles A (April 2002). "Multiple sclerosis". Lancet. 359 (9313): 1221–1231. doi:10.1016/S0140-6736(02)08220-X. PMID 11955556. S2CID 14207583.
Piryonesi SM, Rostampour S, Piryonesi SA (April 2021). "Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms". Multiple Sclerosis and Related Disorders. 49 102740. doi:10.1016/j.msard.2021.102740. PMID 33450500. S2CID 231624230.
Baecher-Allan C, Kaskow BJ, Weiner HL (February 2018). "Multiple Sclerosis: Mechanisms and Immunotherapy". Neuron. 97 (4): 742–768. doi:10.1016/j.neuron.2018.01.021. PMID 29470968. S2CID 3499974.
^{[medical citation needed]}Lublin FD, Reingold SC (April 1996). "Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology. 46 (4): 907–911. doi:10.1212/WNL.46.4.907. PMID 8780061. S2CID 40213123.
Ward M, Goldman MD (August 2022). "Epidemiology and Pathophysiology of Multiple Sclerosis". Continuum. 28 (4): 988–1005. doi:10.1212/CON.0000000000001136. PMID 35938654. S2CID 251375096.
Aloisi F, Cross AH (October 2022). "MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis". Journal of Neuroimmunology. 371 577935. doi:10.1016/j.jneuroim.2022.577935. PMID 35931008. S2CID 251152784.
Ascherio A, Munger KL (April 2007). "Environmental risk factors for multiple sclerosis. Part I: the role of infection". Annals of Neurology. 61 (4): 288–299. doi:10.1002/ana.21117. PMID 17444504. S2CID 7682774.
McGinley MP, Goldschmidt CH, Rae-Grant AD (February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765–779. doi:10.1001/jama.2020.26858. PMID 33620411. S2CID 232019589.
Quinn É, Hynes SM (July 2021). "Occupational therapy interventions for multiple sclerosis: A scoping review". Scandinavian Journal of Occupational Therapy. 28 (5): 399–414. doi:10.1080/11038128.2020.1786160. hdl:10379/16066. PMID 32643486. S2CID 220436640.
Weinshenker BG (1994). "Natural history of multiple sclerosis". Annals of Neurology. 36 (Suppl): S6-11. doi:10.1002/ana.410360704. PMID 8017890. S2CID 7140070.
Berer K, Krishnamoorthy G (November 2014). "Microbial view of central nervous system autoimmunity". FEBS Letters. 588 (22): 4207–13. Bibcode:2014FEBSL.588.4207B. doi:10.1016/j.febslet.2014.04.007. PMID 24746689. S2CID 2772656.
Lane J, Ng HS, Poyser C, Lucas RM, Tremlett H (July 2022). "Multiple sclerosis incidence: A systematic review of change over time by geographical region". Mult Scler Relat Disord. 63 103932. doi:10.1016/j.msard.2022.103932. PMID 35667315. S2CID 249188137.
Benedict RH, Amato MP, DeLuca J, Geurts JJ (October 2020). "Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues". The Lancet. Neurology. 19 (10): 860–871. doi:10.1016/S1474-4422(20)30277-5. PMC 10011205. PMID 32949546. S2CID 221744328.
Amato MP, Ponziani G (August 1999). "Quantification of impairment in MS: discussion of the scales in use". Multiple Sclerosis. 5 (4): 216–9. doi:10.1177/135245859900500404. PMID 10467378. S2CID 6763447.
Rudick RA, Cutter G, Reingold S (October 2002). "The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials". Multiple Sclerosis. 8 (5): 359–65. doi:10.1191/1352458502ms845oa. PMID 12356200. S2CID 31529508.
Marrie RA (December 2019). "Mounting evidence for a multiple sclerosis prodrome". Nature Reviews. Neurology. 15 (12): 689–690. doi:10.1038/s41582-019-0283-0. PMID 31654040. S2CID 204887642.
Tataru N, Vidal C, Decavel P, Berger E, Rumbach L (2006). "Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis". Neuroepidemiology. 27 (1): 28–32. doi:10.1159/000094233. PMID 16804331. S2CID 20870484.
Heesen C, Mohr DC, Huitinga I, Bergh FT, Gaab J, Otte C, et al. (March 2007). "Stress regulation in multiple sclerosis: current issues and concepts". Multiple Sclerosis. 13 (2): 143–148. doi:10.1177/1352458506070772. PMID 17439878. S2CID 8262595.
Martinelli V (2000). "Trauma, stress and multiple sclerosis". Neurological Sciences. 21 (4 Suppl 2): S849 – S852. doi:10.1007/s100720070024. PMID 11205361. S2CID 2376078.
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (January 2022). "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis". Science. 375 (6578): 296–301. Bibcode:2022Sci...375..296B. doi:10.1126/science.abj8222. PMID 35025605. S2CID 245983763. See lay summary: Gallagher J (13 April 2022). "Is a virus we all have causing multiple sclerosis?". BBC. Archived from the original on 25 April 2022. Retrieved 14 April 2022.
Dyment DA, Ebers GC, Sadovnick AD (February 2004). "Genetics of multiple sclerosis". The Lancet. Neurology. 3 (2): 104–10. CiteSeerX 10.1.1.334.1312. doi:10.1016/S1474-4422(03)00663-X. PMID 14747002. S2CID 16707321.
Rosati G (April 2001). "The prevalence of multiple sclerosis in the world: an update". Neurological Sciences. 22 (2): 117–39. doi:10.1007/s100720170011. PMID 11603614. S2CID 207051545.
Pugliatti M, Sotgiu S, Rosati G (July 2002). "The worldwide prevalence of multiple sclerosis". Clinical Neurology and Neurosurgery. 104 (3): 182–91. doi:10.1016/S0303-8467(02)00036-7. PMID 12127652. S2CID 862001.
Grimaldi LM, Salemi G, Grimaldi G, Rizzo A, Marziolo R, Lo Presti C, et al. (November 2001). "High incidence and increasing prevalence of MS in Enna (Sicily), southern Italy". Neurology. 57 (10): 1891–3. doi:10.1212/wnl.57.10.1891. PMID 11723283. S2CID 34895995.
Marrie RA (December 2004). "Environmental risk factors in multiple sclerosis aetiology". The Lancet. Neurology. 3 (12): 709–18. doi:10.1016/S1474-4422(04)00933-0. PMID 15556803. S2CID 175786.
Ascherio A, Munger KL (June 2007). "Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors". Annals of Neurology. 61 (6): 504–13. doi:10.1002/ana.21141. PMID 17492755. S2CID 36999504.
Nourbakhsh B, Mowry EM (June 2019). "Multiple Sclerosis Risk Factors and Pathogenesis". Continuum. 25 (3): 596–610. doi:10.1212/CON.0000000000000725. PMID 31162307. S2CID 174806511.
Pittock SJ, Lucchinetti CF (March 2007). "The pathology of MS: new insights and potential clinical applications". The Neurologist. 13 (2): 45–56. doi:10.1097/01.nrl.0000253065.31662.37. PMID 17351524. S2CID 2993523.
Trojano M, Paolicelli D (November 2001). "The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes". Neurological Sciences. 22 (Suppl 2): S98-102. doi:10.1007/s100720100044. PMID 11794488. S2CID 3057096.
Poser CM, Brinar VV (June 2004). "Diagnostic criteria for multiple sclerosis: an historical review". Clinical Neurology and Neurosurgery. 106 (3): 147–58. doi:10.1016/j.clineuro.2004.02.004. PMID 15177763. S2CID 23452341.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. (July 2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis". Annals of Neurology. 50 (1): 121–7. doi:10.1002/ana.1032. PMID 11456302. S2CID 13870943.
Rashid W, Miller DH (February 2008). "Recent advances in neuroimaging of multiple sclerosis". Seminars in Neurology. 28 (1): 46–55. doi:10.1055/s-2007-1019127. PMID 18256986. S2CID 260317568.
Link H, Huang YM (November 2006). "Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness". Journal of Neuroimmunology. 180 (1–2): 17–28. doi:10.1016/j.jneuroim.2006.07.006. PMID 16945427. S2CID 22724352.
Solomon AJ (June 2019). "Diagnosis, Differential Diagnosis, and Misdiagnosis of Multiple Sclerosis". Continuum. 25 (3): 611–635. doi:10.1212/CON.0000000000000728. PMID 31162308. S2CID 173991777.
Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (May 2005). "Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis". The Lancet. Neurology. 4 (5): 281–8. doi:10.1016/S1474-4422(05)70071-5. PMID 15847841. S2CID 36401666.
Miller DH, Leary SM (October 2007). "Primary-progressive multiple sclerosis". The Lancet. Neurology. 6 (10): 903–12. doi:10.1016/S1474-4422(07)70243-0. hdl:1871/24666. PMID 17884680. S2CID 31389841.
Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M (April 2006). "Secondary progressive multiple sclerosis: current knowledge and future challenges". The Lancet. Neurology. 5 (4): 343–54. doi:10.1016/S1474-4422(06)70410-0. PMID 16545751. S2CID 39503553.
Stadelmann C, Brück W (November 2004). "Lessons from the neuropathology of atypical forms of multiple sclerosis". Neurological Sciences. 25 (Suppl 4): S319 – S322. doi:10.1007/s10072-004-0333-1. PMID 15727225. S2CID 21212935.
McGinley MP, Goldschmidt CH, Rae-Grant AD (February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765–779. doi:10.1001/jama.2020.26858. PMID 33620411. S2CID 232019589.
Freedman MS (January 2011). "Long-term follow-up of clinical trials of multiple sclerosis therapies". Neurology. 76 (1 Suppl 1): S26-34. doi:10.1212/WNL.0b013e318205051d. PMID 21205679. S2CID 16929304.
Bates D (January 2011). "Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials". Neurology. 76 (1 Suppl 1): S14-25. doi:10.1212/WNL.0b013e3182050388. PMID 21205678. S2CID 362182.
Johnston J, So TY (June 2012). "First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview". Drugs. 72 (9): 1195–211. doi:10.2165/11634010-000000000-00000. PMID 22642799. S2CID 20323687.
Killestein J, Rudick RA, Polman CH (November 2011). "Oral treatment for multiple sclerosis". The Lancet. Neurology. 10 (11): 1026–34. doi:10.1016/S1474-4422(11)70228-9. PMID 22014437. S2CID 206160178.
Tremlett H, Oger J (November 2004). "Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis". Journal of Neurology. 251 (11): 1297–303. doi:10.1007/s00415-004-0619-5. PMID 15592724. S2CID 12529733.
Comi G (October 2009). "Treatment of multiple sclerosis: role of natalizumab". Neurological Sciences. 30. 30 (S2): S155-8. doi:10.1007/s10072-009-0147-2. PMID 19882365. S2CID 25910077.
Hunt D, Giovannoni G (February 2012). "Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring". Practical Neurology. 12 (1): 25–35. doi:10.1136/practneurol-2011-000092. PMID 22258169. S2CID 46326042.
Kesselring J, Beer S (October 2005). "Symptomatic therapy and neurorehabilitation in multiple sclerosis". The Lancet. Neurology. 4 (10): 643–52. doi:10.1016/S1474-4422(05)70193-9. PMID 16168933. S2CID 28253186.
Khan F, Amatya B, Bensmail D, Yelnik A (July 2019). "Non-pharmacological interventions for spasticity in adults: An overview of systematic reviews". Ann Phys Rehabil Med. 62 (4): 265–273. doi:10.1016/j.rehab.2017.10.001. PMID 29042299. S2CID 207497395.
Etoom M, Khraiwesh Y, Lena F, et al. (November 2018). "Effectiveness of Physiotherapy Interventions on Spasticity in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis". Am J Phys Med Rehabil. 97 (11): 793–807. doi:10.1097/PHM.0000000000000970. PMID 29794531. S2CID 44156766.
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E (October 2006). "Cannabis use in patients with multiple sclerosis". Multiple Sclerosis. 12 (5): 646–51. doi:10.1177/1352458506070947. PMID 17086912. S2CID 34692470.
Motte J, Gold R (December 2020). "High-dose biotin in multiple sclerosis: the end of the road". Lancet Neurol. 19 (12): 965–966. doi:10.1016/S1474-4422(20)30353-7. PMID 33222766. S2CID 225049079.
Cree BA, Hartung HP, Barnett M (June 2022). "New drugs for multiple sclerosis: new treatment algorithms". Curr Opin Neurol. 35 (3): 262–270. doi:10.1097/WCO.0000000000001063. PMID 35674067. S2CID 249438715.
Ontaneda D (June 2019). "Progressive Multiple Sclerosis". Continuum. 25 (3): 736–752. doi:10.1212/CON.0000000000000727. PMID 31162314. S2CID 174808956.
Inojosa H, Proschmann U, Akgün K, Ziemssen T (April 2021). "A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition". J Neurol. 268 (4): 1210–1221. doi:10.1007/s00415-019-09489-5. PMID 31363847. S2CID 198999832. Expanded Disability Status Scale (EDSS) 6.0 is equivalent to requiring a walking aid, and EDSS 8.0 equivalent to chair or bedbound
Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (April 2018). "Multiple sclerosis". Lancet. 391 (10130): 1622–1636. doi:10.1016/S0140-6736(18)30481-1. PMID 29576504. S2CID 4313310.
Lassmann H (July 2005). "Multiple sclerosis pathology: evolution of pathogenetic concepts". Brain Pathology. 15 (3): 217–22. doi:10.1111/j.1750-3639.2005.tb00523.x. PMC 8095927. PMID 16196388. S2CID 8342303.
Medaer R (September 1979). "Does the history of multiple sclerosis go back as far as the 14th century?". Acta Neurologica Scandinavica. 60 (3): 189–92. doi:10.1111/j.1600-0447.1979.tb08970.x. PMID 390966. S2CID 221422840.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. (January 2017). "Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis". The New England Journal of Medicine. 376 (3): 221–234. doi:10.1056/NEJMoa1601277. hdl:2445/178507. PMID 28002679. S2CID 205099904.
Li Y, Fan T, Cui J (March 2022). "Human endogenous retroviruses in viral disease and therapy". Clinical and Translational Discovery. 2 (1) e38. doi:10.1002/ctd2.38. S2CID 247750447.

sickkids.ca (Global: low place; English: low place)

lab.research.sickkids.ca

"Visual & Neurocognitive Outcomes". Paediatric Neuroinflammatory Disorders Program. Archived from the original on 30 July 2024. Retrieved 30 July 2024.

statnews.com (Global: 8,771^st place; English: 5,253^rd place)

Winslow R (28 March 2017). "After 40-year odyssey, first drug for aggressive MS wins FDA approval". STAT. Archived from the original on 1 April 2017.

theguardian.com (Global: 12^th place; English: 11^th place)

Adams T (23 May 2010). "Gut instinct: the miracle of the parasitic hookworm". The Observer. Archived from the original on 24 October 2014.

ucl.ac.uk (Global: 1,306^th place; English: 885^th place)

discovery.ucl.ac.uk

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. (February 2018). "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria". The Lancet. Neurology. 17 (2): 162–173. doi:10.1016/s1474-4422(17)30470-2. PMID 29275977. Archived from the original on 28 May 2023. Retrieved 20 January 2024.
Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. (October 2018). "Neurofilaments as biomarkers in neurological disorders". Nature Reviews. Neurology. 14 (10): 577–589. doi:10.1038/s41582-018-0058-z. PMID 30171200.
Petzold A (June 2005). "Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss". Journal of the Neurological Sciences. 233 (1–2): 183–98. doi:10.1016/j.jns.2005.03.015. PMID 15896809.

ufms.br (Global: low place; English: low place)

repositorio.ufms.br

Oh J, Vidal-Jordana A, Montalban X (December 2018). "Multiple sclerosis: clinical aspects". Curr Opin Neurol. 31 (6): 752–759. doi:10.1097/WCO.0000000000000622. PMID 30300239. Archived from the original on 25 November 2024. Retrieved 2 June 2024.

vu.nl (Global: 8,540^th place; English: 6,274^th place)

research.vu.nl

Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH (May 2005). "Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews". Clinical Rehabilitation. 19 (3): 247–54. doi:10.1191/0269215505cr870oa. hdl:1871/26505. PMID 15859525.

washingtonpost.com (Global: 34^th place; English: 27^th place)

Johnson CY (10 January 2024). "Ancient DNA helps trace multiple sclerosis origins in European descendants". Washington Post. Archived from the original on 17 August 2024. Retrieved 11 January 2024.

web.archive.org (Global: 1^st place; English: 1^st place)

"NINDS Multiple Sclerosis Information Page". National Institute of Neurological Disorders and Stroke. 30 June 2025. Archived from the original on 4 June 2025. Retrieved 30 June 2025.
"The McDonald criteria". MS Society UK. 31 May 2023. Archived from the original on 2 December 2024. Retrieved 26 November 2024.
"Fatigue". Letchworth Garden City, United Kingdom: Multiple Sclerosis Trust. Archived from the original on 16 January 2024. Retrieved 16 January 2024.
"MS Signs". Webmd. Archived from the original on 30 September 2016. Retrieved 7 October 2016.
"Pregnancy, birth, breastfeeding and MS". Multiple Sclerosis Society. Archived from the original on 8 April 2024. Retrieved 8 April 2024.
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (January 2022). "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis". Science. 375 (6578): 296–301. Bibcode:2022Sci...375..296B. doi:10.1126/science.abj8222. PMID 35025605. S2CID 245983763. See lay summary: Gallagher J (13 April 2022). "Is a virus we all have causing multiple sclerosis?". BBC. Archived from the original on 25 April 2022. Retrieved 14 April 2022.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. (February 2018). "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria". The Lancet. Neurology. 17 (2): 162–173. doi:10.1016/s1474-4422(17)30470-2. PMID 29275977. Archived from the original on 28 May 2023. Retrieved 20 January 2024.
Bernitsas E (February 2020). "The Central Vein Sign". Practical Neurology. Archived from the original on 5 October 2021. Retrieved 5 October 2021.
Chapman M (16 June 2020). "$7.2M NIH Grant Supports Study of MS Diagnostic Biomarker". BioNews Services. Archived from the original on 5 October 2021. Retrieved 5 October 2021.
"Clinically Isolated Syndrome (CIS)". National MS Society. Archived from the original on 30 September 2023. Retrieved 4 October 2023.
"Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease". Novartis.com. Archived from the original on 20 November 2020. Retrieved 12 November 2021.
The National Collaborating Centre for Chronic Conditions (2004). "Treatment of acute episodes". Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians. pp. 54–58. ISBN 1-86016-182-0. PMID 21290636. Archived from the original on 10 February 2023. Retrieved 5 October 2021.
"TG Therapeutics Announces FDA Approval of Briumvi (ublituximab-xiiy)" (Press release). TG Therapeutics. 28 December 2022. Archived from the original on 28 December 2022. Retrieved 29 December 2022 – via GlobeNewswire.
"MS Decisions aid". Letchworth Garden City, United Kingdom: Multiple Sclerosis Trust. 3 December 2023. Archived from the original on 3 December 2023. Retrieved 3 December 2023.
Winslow R (28 March 2017). "After 40-year odyssey, first drug for aggressive MS wins FDA approval". STAT. Archived from the original on 1 April 2017.
"Ocrevus- ocrelizumab injection". DailyMed. 13 December 2019. Archived from the original on 27 June 2020. Retrieved 26 March 2020.
"BLA Approval Letter" (PDF). FDA. 28 March 2017. Archived from the original (PDF) on 2 April 2017.
"FDA Approves Ocrevus Zunovo as the First and Only Twice-A-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis". Genentech (Press release). 13 September 2024. Archived from the original on 14 September 2024. Retrieved 13 September 2024.
"Halozyme Announces FDA Approval of Roche's Subcutaneous Ocrevus Zunovo with Enhanze for People with Relapsing and Primary Progressive Multiple Sclerosis" (Press release). Halozyme Therapeutics. 13 September 2024. Archived from the original on 14 September 2024. Retrieved 13 September 2024 – via PR Newswire.
"Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis" (Press release). Biogen Idec. 27 March 2013. Archived from the original on 12 May 2013. Retrieved 4 June 2013.
"NDA 204063 – FDA Approved Labeling Text" (PDF). US Food and Drug Agency. 27 March 2013. Archived (PDF) from the original on 4 October 2013. Retrieved 5 April 2013.
"NDA Approval" (PDF). US Food and Drug Agency. 27 March 2013. Archived from the original (PDF) on 4 October 2013. Retrieved 5 April 2013.
Adams T (23 May 2010). "Gut instinct: the miracle of the parasitic hookworm". The Observer. Archived from the original on 24 October 2014.
Oh J, Vidal-Jordana A, Montalban X (December 2018). "Multiple sclerosis: clinical aspects". Curr Opin Neurol. 31 (6): 752–759. doi:10.1097/WCO.0000000000000622. PMID 30300239. Archived from the original on 25 November 2024. Retrieved 2 June 2024.
"New treatment hope as world-first MS mega-trial opens site in Northern Ireland". www.qub.ac.uk. 6 June 2023. Archived from the original on 30 July 2024. Retrieved 30 July 2024.
"Can metformin and clemastine repair myelin in people with MS?". MS Society UK. Archived from the original on 30 July 2024. Retrieved 30 July 2024.
"Visual & Neurocognitive Outcomes". Paediatric Neuroinflammatory Disorders Program. Archived from the original on 30 July 2024. Retrieved 30 July 2024.
"Metformin". Multiple Sclerosis Society. Archived from the original on 30 July 2024. Retrieved 30 July 2024.
Johnson CY (10 January 2024). "Ancient DNA helps trace multiple sclerosis origins in European descendants". Washington Post. Archived from the original on 17 August 2024. Retrieved 11 January 2024.
Roxby P (10 January 2024). "Scientists crack mystery of how MS gene spread". BBC News. Archived from the original on 11 January 2024. Retrieved 11 January 2024.
"Novel Study Suggests that MS was Brought to Northern Europe 5,000 Years Ago". National MS Society. 10 January 2024. Archived from the original on 11 January 2024. Retrieved 11 January 2024.

webmd.com (Global: 1,169^th place; English: 1,075^th place)

"MS Signs". Webmd. Archived from the original on 30 September 2016. Retrieved 7 October 2016.

wiley.com (Global: 222^nd place; English: 297^th place)

onlinelibrary.wiley.com

Dobson R, Giovannoni G (2019). "Multiple sclerosis – a review". European Journal of Neurology. 26 (1): 27–40. doi:10.1111/ene.13819. ISSN 1468-1331. PMID 30300457.
Dobson R, Giovannoni G (2019). "Multiple sclerosis – a review". European Journal of Neurology. 26 (1): 27–40. doi:10.1111/ene.13819. ISSN 1468-1331. PMID 30300457.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Ford H (July 2020). "Clinical presentation and diagnosis of multiple sclerosis". Clinical Medicine. 20 (4). London, England: 380–383. doi:10.7861/clinmed.2020-0292. ISSN 1473-4893. PMC 7385797. PMID 32675142.
Wecker S, Freudenstein D, Ganser I, Angstwurm K, Lee DH, Linker RA (2024). "The impact of different lifestyle factors on disability in multiple sclerosis at older ages: a monocentric retrospective study". Therapeutic Advances in Neurological Disorders. 17 17562864241284166. doi:10.1177/17562864241284166. ISSN 1756-2856. PMC 11528639. PMID 39494114.
Dobson R, Giovannoni G (2019). "Multiple sclerosis – a review". European Journal of Neurology. 26 (1): 27–40. doi:10.1111/ene.13819. ISSN 1468-1331. PMID 30300457.
Dobson R, Giovannoni G (2019). "Multiple sclerosis – a review". European Journal of Neurology. 26 (1): 27–40. doi:10.1111/ene.13819. ISSN 1468-1331. PMID 30300457.
McGinley MP, Goldschmidt CH, Rae-Grant AD (23 February 2021). "Diagnosis and Treatment of Multiple Sclerosis: A Review". JAMA. 325 (8): 765. doi:10.1001/jama.2020.26858. ISSN 0098-7484.
Sintzel MB, Rametta M, Reder AT (1 June 2018). "Vitamin D and Multiple Sclerosis: A Comprehensive Review". Neurology and Therapy. 7 (1): 59–85. doi:10.1007/s40120-017-0086-4. ISSN 2193-6536. PMC 5990512. PMID 29243029.
Olsson T, Barcellos LF, Alfredsson L (January 2017). "Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis". Nature Reviews Neurology. 13 (1): 25–36. doi:10.1038/nrneurol.2016.187. ISSN 1759-4766. PMID 27934854.
Miclea A, Bagnoud M, Chan A, Hoepner R (6 May 2020). "A Brief Review of the Effects of Vitamin D on Multiple Sclerosis". Frontiers in Immunology. 11 781. doi:10.3389/fimmu.2020.00781. ISSN 1664-3224. PMC 7218089. PMID 32435244.
Hauser SL (2022). "Chapter 442: Diseases of the Spinal Cord". In Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds.). Harrison's principles of internal medicine (21st ed.). New York: McGraw-Hill. p. 3466. ISBN 978-1-264-26849-8. OCLC 1282172709.

Multiple sclerosis (English Wikipedia)

aafp.org (Global: 1,916th place; English: 1,419th place)

aan.com (Global: low place; English: low place)

continuum.aan.com

archive.org (Global: 6th place; English: 6th place)

atlasofms.org (Global: low place; English: low place)

bbc.com (Global: 20th place; English: 30th place)

biogenidec.com (Global: low place; English: low place)

books.google.com (Global: 3rd place; English: 3rd place)

doi.org (Global: 2nd place; English: 2nd place)

fda.gov (Global: 447th place; English: 338th place)

accessdata.fda.gov

gene.com (Global: low place; English: low place)

globenewswire.com (Global: 2,614th place; English: 1,549th place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

jamanetwork.com (Global: 2,650th place; English: 3,409th place)

msif.org (Global: low place; English: low place)

mssociety.org.uk (Global: low place; English: low place)

mstrust.org.uk (Global: low place; English: low place)

multiplesclerosisnewstoday.com (Global: low place; English: low place)

nationalmssociety.org (Global: low place; English: low place)

nature.com (Global: 234th place; English: 397th place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

ninds.nih.gov

dailymed.nlm.nih.gov

novartis.com (Global: low place; English: low place)

practicalneurology.com (Global: low place; English: low place)

prnewswire.com (Global: 406th place; English: 258th place)

psu.edu (Global: 207th place; English: 136th place)

citeseerx.ist.psu.edu

qub.ac.uk (Global: 8,565th place; English: 5,337th place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

sickkids.ca (Global: low place; English: low place)

lab.research.sickkids.ca

statnews.com (Global: 8,771st place; English: 5,253rd place)

theguardian.com (Global: 12th place; English: 11th place)

ucl.ac.uk (Global: 1,306th place; English: 885th place)

discovery.ucl.ac.uk

ufms.br (Global: low place; English: low place)

repositorio.ufms.br

vu.nl (Global: 8,540th place; English: 6,274th place)

research.vu.nl

washingtonpost.com (Global: 34th place; English: 27th place)

web.archive.org (Global: 1st place; English: 1st place)

webmd.com (Global: 1,169th place; English: 1,075th place)

wiley.com (Global: 222nd place; English: 297th place)

onlinelibrary.wiley.com

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

aafp.org (Global: 1,916^th place; English: 1,419^th place)

archive.org (Global: 6^th place; English: 6^th place)

bbc.com (Global: 20^th place; English: 30^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

doi.org (Global: 2^nd place; English: 2^nd place)

fda.gov (Global: 447^th place; English: 338^th place)

globenewswire.com (Global: 2,614^th place; English: 1,549^th place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

jamanetwork.com (Global: 2,650^th place; English: 3,409^th place)

nature.com (Global: 234^th place; English: 397^th place)

nih.gov (Global: 4^th place; English: 4^th place)

prnewswire.com (Global: 406^th place; English: 258^th place)

psu.edu (Global: 207^th place; English: 136^th place)

qub.ac.uk (Global: 8,565^th place; English: 5,337^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

statnews.com (Global: 8,771^st place; English: 5,253^rd place)

theguardian.com (Global: 12^th place; English: 11^th place)

ucl.ac.uk (Global: 1,306^th place; English: 885^th place)

vu.nl (Global: 8,540^th place; English: 6,274^th place)

washingtonpost.com (Global: 34^th place; English: 27^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

webmd.com (Global: 1,169^th place; English: 1,075^th place)

wiley.com (Global: 222^nd place; English: 297^th place)

worldcat.org (Global: 5^th place; English: 5^th place)